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Abstract
The transcription factor grainyhead like 2 is a novel suppressor of the epithelial to mesenchymal
transition
Benjamin Cieply

The epithelial to mesenchymal transition (EMT) is a process that is essential for normal embryonic
development as well as the healing of damaged adult tissues. In the context of cancer, oncogenic EMT induces
enhanced invasion, survival and tumorigenicity which can promote disease progression and recurrence after
therapy. Many factors that induce EMT during development and in culture are known and these include the
transcription factors Twist, Snail1/2, ZEB1/2 and goosecoid. Transforming growth factor β can induce EMT
both in the contexts of wound healing and cancer, but some cell types are resistant to this stimulus.
Furthermore, knowledge of factors which stabilize the epithelial phenotype is limited but include the bone
morphogenic protein family of ligands, the epithelial splicing regulatory proteins, and the mir200 micro-RNAs.
However, transcription factors which suppress EMT remain surprisingly elusive. In pursuit of identifying such
a factor we searched EMT microarrays for transcription factors which were downregulated and that had been
previously known to regulate the EMT related process of wound healing. Grainy-head-like-2 (GRHL2) met
these criteria so we tested its role in regulating EMT. We found that GRHL2 induced mesenchymal to
epithelial transition (MET) and antagonized Twist induced EMT. Also, knockdown of GRHL2 made mammary
epithelial cells permissive to TGF-β induced EMT. GRHL2 knockdown in the presence of activated HRAS
induced EMT which was dependent on autocrine TGF-β. The effect of GRHL2 was depended on direct
repression of the ZEB1 promoter where it antagonized homeo-protein mediated transactivation. GRHL2 acted
as a tumor suppressor as it enhanced anoikis, suppressed anchorage independent growth and invasion, and
prevented tumor formation in xenograft assays. Wnt and TGF-β were shown to down regulate GRHL2 by upregulating ZEB1 which directly repressed its promoter. This body of work has identified GRHL2 as novel
suppressor of EMT and tumorigenicity, which engages in a reciprocal repression loop with the EMT inducing
oncogene ZEB1.
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Chapter 1
Introduction and Literature Review
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Epithelial to Mesenchymal Transition
Epithelial vs. mesenchymal phenotypes
Epithelial tissues commonly function as barriers which separate physiologically distinct compartments
of multi-cellular organisms, for example, the lining of the gastrointestinal tract of mammals.

Epithelial cells

comprise such barriers and it is their gene expression profile which allows them to do so. The epithelial cell
gene expression program is aimed at achieving two major characteristics: cell-cell adhesion and cell polarity,
both of which are essential for the proper function of epithelial tissues. Epithelial-cadherin, or E-cadherin, is an
integral membrane protein whose extracelluar domain interacts homophilically with the adjacent cell’s Ecadherin. The intracellular domain is the hub of a complex which regulates cortical actin assembly, cell
polarity, signaling and gene expression, all of which contribute to the epithelial phenotype [1] [2]. The
physical, fluid impermeable barrier of epithelial tissues is established by tight junctions (TJ) which are made up
of epithelial specific 4-spanning transmembrane proteins, claudins and occludins. TJs also contribute to cell
polarity by restricting the diffusion of integral membrane proteins between apical and baso-lateral membranes.
[3,4]. The apical membrane of a polarized epithelial cell faces the lumen of a vessel and the baso-lateral
membrane is attached to the adjacent cell and extracellular matrix. Epithelial cells are dependent on their basolateral membrane interactions for survival (see anoikis below). Epithelial cell polarity is critical for the proper
function of the tissues that they comprise. For example, intestinal epithelial cells must have distinct glucose
transporters localized to apical and baso-lateral membranes in order to facilitate the transcellular transport of
glucose from the intestinal lumen into the blood.[5] The proper localization of epithelial transmembrane
proteins is regulated by epithelial specific cytosolic vesicular transport involving genes such as ankyrin-G and
RAB-25[6,7]. Apical-basolateral polarity is not only essential for the proper function of epithial tissues, it also
has a tumor suppressive effect to be detailed below.
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In contrast to epithelial cells, all of the aforementioned genes are down-regulated/not expressed in
mesenchymal cells, rendering mesenchymal cells incapable of interacting with adjacent cells to form barriers or
layers. Mesenchymal cells lack the apical-basolateral polarity and are not as dependent on matrix interactions
for survival.[8] They also exhibit an enhanced likelihood to migrate as individual cells.[9] Examples of
mesenchymal cells in adult organisms are fibroblasts and mesenchymal stem cells(MSC). Fibroblasts exist
within the stromal compartment of tissues and function to synthesize the extracellular matrix. MSCs are an
example of adult stem cells which can differentiate into osteoblasts, adipocytes and chondrocytes[10]
Microarray analysis of epithelial vs. mesenchymal cells reveals significant changes in the expression of several
hundred genes, which further emphasizes the distinct epigenetic and phenotypic contrast between these two cell
types.[11]

Physiological roles of EMT/MET
The stark contrast of epithelial and mesenchymal cell types is clear; however, cellular plasticity
between these two distinct phenotypes has been widely documented and investigated. These processes have
been termed either epithelial-mesenchymal-transition (EMT) or mesencymal-epithelial-transition (MET). EMT
during embryonic development is essential, in fact, embryos lacking the EMT inducing transcription factors
Snail 1 and 2 fail to gastrulate due to stable epithelial junctions of mesodermal cells which impede their
migration to form the primitive streak. [12] [13]. Soon after primitive streak formation another example of
epithelial/mesenchymal plasticity can be observed where epithelial junctions are required for proper neural tube
closure [14-16] followed by an EMT required for neural crest delamination. These cells then migrate away
from the neural tube and undergo an MET to form structures such as the notochord and somites. [17]. Later in
development EMT/MET cycles can be observed during the formation of organs such as the heart and
kidney.[17,18]
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In adult organisms, EMT has been implicated in regulating wound healing, inducing fibrosis and
malignant progression of cancer. During epidermal wound healing, myofibroblasts are required for wound
contractility as well as rebuilding the extracellular matrix; a portion of this cell population is generated through
EMT mediated transdifferentiation of keratinocytes. Also, the keratinocytes at the leading edge of the wound
exhibit a partial EMT which facilitates migration of the attached epithelial sheet. [19-21] [22,23]. An example
of EMT contributing to disease pathogenesis is in fibrotic tissue where a significant fraction of the fibroblasts
(and myofibroblasts), which produce the excess collagen and thus fibrosis, are generated via TGF-β induced
EMT of the epithelial cells within the organ. [17,24,25]
Oncogenic roles of EMT
Most of the attributes of a tumor cell which contribute to its malignancy originated as normal processes
within the organism but are improperly regulated in the context of the tumor. The most obvious example of this
is cell proliferation and growth. EMT is another example, and as described above it is an essential process for
normal development and wound healing. However, when employed inappropriately by a tumor cell, EMT can
contribute to multiple facets of malignant progression. These are described in detail below.
Cancer stem cell/ tumor initiating cells and EMT
The hypothesis that malignancies are driven by tumor specific stem cells has long been investigated and
discussed in the hematopoietic field dating back to 1967; Daniel Bergsagel said that “...studies will have to be
initiated to elucidate the properties of the two types of stem cells so that therapeutic measures can be developed
to eliminate the leukemic stem line...” [26]. Roughly 30 years later, experimental evidence began to emerge
showing that, only a specific sub-fraction of primary leukemic cells were able to recapitulate the disease in mice
while the vast majority of the cells could not, these became known as leukemic stem cells.[27-29]
Subsequently, it was found that, (using the same criteria, namely, the ability to seed tumors in mice) an
analogous population existed in solid tumors, and were coined “cancer stem cells” or “tumor initiating
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cells(TIC)”. [30,31] As in leukemia, the tumor initiating cells of solid tumors made up only a very small
fraction of the cells. Since these initial studies, it has been demonstrated that the proportion of CSC in a tumor
population can vary dramatically between patients and tumor types, but it is consistent that tumors are
comprised of at least 2 distinct populations: tumorigenic and non-tumorigenic.[32] Tumor heterogeneity and
the existence of TICs represents a daunting complication with respect to patient treatment because even a single
TIC left alive after treatment can drive the recurrence of the entire disease and a single TIC that has
disseminated from the primary tumor can drive the formation of a distant metastasis. On the other hand they
represent exciting opportunity, as TIC specific targeted therapies would revolutionize cancer treatment.
Because of this, TICs and CSCs are at the center of an entire field of cancer research.
The origin of CSCs or TICs is controversial [32]. In breast cancer, one model which has been
elucidated is that TIC/CSC’s can be generated from non-tumorigenic/non-CSC population via a passage
through the EMT. Al-Hajj et al. 2003, used the surface antigenic phenotype of CD44HIGH/CD24LOW to isolate
tumorigenic cells from heterogeneous tumor cell populations. Mani et al. 2008, then showed that immortalized
mammary epithelial cells acquired a CD44HIGH/CD24LOW and tumorigenic phenotype after having undergone
EMT [33]. Since that discovery there have been numerous reports linking EMT with TIC properties in breast
and other types of cancer cells. [9, 34,35]. This theoretically raises the possibility that any cell with-in a
carcinoma can become a TIC, if, first they are induced to undergo an EMT. This confounds even further the
paradigm of tumor heterogeneity, but, it identified a tangible characteristic of this otherwise enigmatic cell
population providing the rationale for investigating the EMT process with the aim of identifying TIC/CSCs
specific drugable targets.
EMT and anoikis
Anoikis is a term that describes the phenomenon where epithelial cells are dependent on their matrix
attachment for survival and detatchement from appropriate matrix induces apoptosis[8]. The apoptosis
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mechanism induced by detachment is not specific to this context and is regulated by common pro and antiapoptotic genes.

What establishes anoikis sensitivity has been the underlying question in the field since its

discovery. A clue to the answer of this question was included in the original anoikis report showing that
epithelial cells and not mesenchymal cells were sensitive.[8] Consistent with this finding, it has become well
established that EMT induces anoikis resistance [36-38] and the mechanisms for this are emerging.
E-cadherin and anoikis
E-cadherin is at the center of at least three anoikis sensitizing complexes. We recently reported that the
epithelial specific cytoskeletal and E-cadherin associated gene, ankyrinG, sequestered a transcription factor,
NRAGE, in the cytoplasm preventing its repression of the pro-apoptotic gene p14ARF. The EMT mediated
down regulation of ankryin G and E-cadherin expression led to the nuclear translocation of NRAGE, repression
of p14 ARF and anoikis resistance.[39] In another report, E-cadherin knockdown induced anoikis resistance,
an effect mediated in part by beta-catenin hypophosphorylation, stabilization, and nuclear translocation[40]
Also, homophilic interaction of E-cadherins engages the Hippo pathway[41](HIPPO regulation of anoikis is
detailed below). In summary, E-cadherin can sensitize epithelial cells to anoikis by regulating:
ankyrinG/NRAGE/p14ARF axis, Wnt/beta-catenin, and HIPPO, but this is unlikely a comprehensive view of Ecadherin’s role in anoikis and this will be a subject of future research.
Epithelial cell polarity, HIPPO, Wnt, TGF-β, and anoikis
Disruption of epithelial apical/baso-lateral polarity is associated with EMT and this is a result of downregulation and/or mis-localization of key polarity complexes [42-44] These polarity complexes define the
distinct membranes of epithelial cells and are the apical membrane complex CRUMBS, the apical/basolateral
border complex composed of PAR genes, and the baso-lateral complex scribble. [45,46] There is substantial
evidence that epithelial cell polarity is critical for anoikis sensitivity due to activation of the HIPPO (LATS in
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human) kinase cascade that leads to the cytoplasmic sequestration of the YAP/TAZ transcriptional co-activators
as well as inhibition of Wnt and TGF-β signalling. Evidence that supports this model is summarized as follows.
The HIPPO kinase signaling pathway is essential for establishing the proper size of organs during
development. ([47]). The cue that engages the HIPPO cascade is cell-cell contacts that in turn promote the
formation of the epithelial cell polarity complexes crumbs and scribble; the HIPPO signaling components
interact with these polarity complexes leading to the phosphorylation and sequestration of YAP/TAZ. [48-50]
Based on recent findings a strong case can be made that sequestration of YAP/TAZ establishes epithelial cell
sensitivity to anoikis. Luminal clearance in the MCF10a mammary mophogeneiss assay, a process mediated by
anoikis was shown to be dependent on scribble and cell polarity [51].

A link between YAP/TAZ and anoikis

was first reported by Zhao et al where detachment from matrix caused YAP phosphorylation(and inactivation),
which proved to be essential for anoikis sensitivity. However the targets of YAP/TAZ, prevent anoikis, where
not identified. [52] Cordenonsi et al.[50] showed that EMT caused the mis-localization of scribble from cell
contact, which activated TAZ, and enhanced the formation of mammospheres (anchorage independent, anoikis
resistant colonies). In this report, TAZ activation induced expression of the apoptosis inhibitor survivin, but its
functional significance was not investigated. A worthy hypothesis, which remains to be tested, is that 1. EMT
induces the loss of epithelial cell polarity complexes leading to the inactivation of HIPPO signaling, and
activation of YAP/TAZ, then 2. YAP/TAZ activate the expression of anti-apoptotic genes such as survivin 3.
suppresses anoikis. The connections between 1-2 and 2-3 remain to be experimentally supported. It is also
interesting to note that confluent cells are significantly more sensitive to anoikis[53] and it is in confluent cells
that Hippo kinase cascade is engaged. Whether Hippo is involved in the difference in anoikis sensitivity
between sub-confluent and confluent cells also remains to be tested.
Aside from inhibiting direct transactivation of YAP/TAZ pro-survival gene targets, HIPPO/LATS
mediated sequestration of YAP/TAZ can inhibit Wnt and TGF-β through protein-protein interactions between
7

YAP/TAZ and Wnt and TGF-β pathway components. First, the TGF-β 1/ TGF-βR1/R2 activated, Smad3, was
shown to exist in a complex with YAP/TAZ; crumbs-LATS mediated phosphorylation and sequestration of
YAP/TAZ caused cytoplasmic sequestration of Smad3. This effectively inhibited TGF-β/Smad3 mediated
transactivation. Second, cytoplasmic TAZ also interacted with and inhibited disheveled, which maintained
GSK3β activity and β-catenin degradation thus inhibiting canonical Wnt signaling [49,54,55]. Neither study
assayed for anoikis, however, the protective effects of Wnt and TGF-β signaling are known [40,56] and these
data further support a role for polarity complex induced HIPPO/LATS activation in establishing anoikis
sensitivity. It does, however establish a dual role for YAP/TAZ depending on their localization; in the nucleus
they activate pro-survival genes that inhibit anoikis, on the other hand in the cytoplasm, they mediate the
HIPPO/LATS induced inhibition of Wnt and TGFβ. Regardless, it is clear that engagement of the
HIPPO/LATS pathway by cell contacts and polarity complexes is critical for epithelial cell sensitivity to
anoikis, and loss of epithelial cell polarity associated with EMT can partially explain the gain of anoikis
resistance.
To summarize, E-cadherin and polarity complexes establish epithelial cell sensitivity to anoikis by
sequestering pro-survival transcription factors such as NRAGE, β-catenin, Smad3, YAP and TAZ in the
cytoplasm. Many of the detailed mechanisms involved remain unclear. For example, how do (if either) Ecadherin and polarity complexes directly activate the LATS kinase cascade and are their functions dependent on
one another? Which TGF-β/Smad3 target genes are essential for anoikis resistance? Do Smad independent
functions of TGF-β inhibit anoikis? These questions and others will require future investigation.
Invasion
One of the most well known aspects of oncogenic EMT is the acquisition of invasive properties. The
major characteristic that links EMT to invasion is the loss of E-cadherin expression. It has been widely
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documented that the cell-cell interaction mediated by E-cadherin favors a state where the cells are much less
likely to invade the surrounding matrix. In fact, expression of ectopic E-cadherin prevented invasion in cancer
cell lines; and clinically E-cadherin loss is used as a marker of invasive cancer by pathologists. [57-61] The
mechanism involved in E-cadherin mediated suppression of invasion, could involve any one of the pathways
that it is known to interact with, some of which are described above. However, a more simplistic perspective is
that it is more energetically favorable for the extracellular domain of E-cadherin to interact with the E-cadherin
molecules of an adjacent epithelial cell than with components of extracellular matrix. The relative abundance
of E-cadherin on the surface of epithelial cells would make this explanation plausible and suggest that Ecadherin prevents invasion physically, rather than biologically. This model is supported by results where the
anti-invasive effect of E-cadherin was reversed by an E-cadherin blocking antibody, which suggests that the
extracellular homophillic E-cadherin interactions were preventing invasion[57,62].
A second physical barrier exists to prevent invasion of epithelial cells and that is the extracellular
matrix. Increased MMP expression and secretion is also associated with EMT and contributes to invasion.
Upregulation of MMPs 1, 2, and 9 have been shown to be associated with EMT and enhanced MMP expression
allows a recently EMT’d tumor cell to degrade matrix after it has down regulated E-cadherin and detached from
its epithelial cell-cell associations[63-66]. Single cell motility is also enhanced by EMT and this effect has been
attributed to upregulation of mesenchymal genes such as vimentin, CD44, hyaluronan synthase 2 and
fibronectin [67-72]. Overall, EMT increases a tumor cell’s ability to invade away from the primary tumor and
through the extracellular matrix due to loss of epithelial adhesion genes, gain of MMPs which degrade matrix,
and gain of genes that enhance single cell motility.

Chemoresistance and evasion of immune surveillance
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The advantage of a mesenchymal phenotype with respect to immune surveillance has been supported by
in vivo evidence. Injection of tumor cell lines into immune- competent mice resulted in the expected immune
response and rejection. However, in some cases the tumors arose over time and exhibited a distinct
mesenchymal morphology and gene expression profile suggesting that EMT contributed to the evolution of an
immune-resistant tumor. [73] A mechanism was not proposed, however in a separate study, it was shown that
EMT and the associated TGF-β secretion resulted in the activation of regulatory T-cells, which induced immune
avoidance and tumor progression [74]. Similar to the pro-survival effect that EMT invokes in the context of
immune surveillance, it has been displayed by various groups that EMT induces resistance to
cytotoxic(chemical agent), radiation and even some targeted cancer therapies, [75-78].
In some experimental contexts MET was shown to enhance metastatic colonization and in fact, has been
proposed as a requirement for the formation of secondary tumors.[79] Therefore, regulators of EMT/MET
could be observed as tumor suppressive or oncogenic depending on the stage of tumor progression under
investigation. Nevertheless, the recurring theme observed when studying the phenotypes associated with EMT
in the context of cancer is enhanced tumor cell survival and increased aggressiveness. Resistance to cell death
induced by loss of matrix association (anoikis), immune surveillance, and therapeutic interventions can be
acquired by a tumor cell via EMT. In addition, EMT induces local invasiveness and tumorigenicity/posttherapy recurrence; and the TIC/CSC properties of EMT’d tumor cells is still of great interest even in the
context where MET was needed to produce the parenchyma of a distant metastasis.

The gene expression,

signaling, and cellular mechanisms that regulate each of these malignant properties are rational targets for the
research and development of novel cancer therapies; however, theoretically, a treatment strategy that inhibited
or reversed EMT would have a multi-faceted and potentially profound effect. The hope of cancer researchers
who study EMT mechanisms is to identify molecular targets, which could be manipulated for this purpose.
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Micro environmental and transcriptional regulation of EMT, as is currently understood, is summarized in the
next section.
Regulation of EMT
EMT inducing transcription factors
As can be deduced from the above section, the most distinct and impactful molecular changes associated
with EMT is the loss of epithelial gene expression. For example, it is the loss of polarity genes that liberates the
pro-survival transcription factors YAP and TAZ to protect cells from anoikis, and the loss of E-cadherin
suffices to enhance invasion. Consistent with this, many of the established EMT inducing factors are
transcriptional repressors of epithelial genes. Snail and ZEB family of transcription factors are the direct
repressors of epithelial genes and bind to E-boxes (DNA sequences resembling CANNTG) in the upstream
promoter region and recruit repressors such as CTBP (ZEB1) and PRC2 (Snail) to silence gene expression and
induce EMT [80-83]. Other EMT inducing transcription factors include Twist, goosecoid, FOXC2 and their
expression leads to epithelial gene repression albeit indirectly, and in most cases through up-regulation of Snail
and/or ZEB repressors[11,17]. In accordance with the oncogenic role of EMT, expression of these transcription
factors has been shown to be associated with malignant progression in mouse models and human cancer
[11,84]; Hartwell, 2006 #3}[85-87].
More recently numerous members of the homeobox transcription factor super family have been reported
to induce oncogenic EMT, these include: LBX1, SIX1, DLX4, and prospero homoebox 1. SIX1 and LBX1
were identified as activators of ZEB1 expression, the LBX1 effect being a direct transactivation while the
mechanism of SIX1 remained unclear. [88-94] These results are consistent with the role of homeoproteins in
the induction of developmental EMT [95,96], it is also interesting to note that well characterized inducers of
EMT, goosecoid and ZEB1 are homeobox genes. A comprehensive view of homoebox transcription factors
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that regulate EMT will require further research, and perhaps more systematic approaches due to the vast size of
this family of genes.
TGF-β
The TGF-β family of ligands and the cellular responses they induce in the context of development,
physiology and disease are at the center of a massive field of research. The TGF-β signally pathway is fairly
well characterized molecularly. There are around 30 genes in the TGF-β family but we will focus on two sub
classes: TGFβ and BMP. TGF-β ligands bind to TGF-βR1/R2 heterodimer which serine phosphorylate Smad2
and 3 inducing their nuclear translocation. In the same manner BMP ligands bind BMPR1A/R1B heterodimer
phosphorylating Smad 1 and 5. In each case the “R” Smads (1, 2, 3, 5) interact with Smad 4 in the nucleus to
modulate transcription.
The target genes activated by TGF-β/Smad3 vary from the growth inhibitor p15 to the EMT inducer
ZEB1 [97,98]. Depending on which is activated by TGF-β, the overall effect can be tumor suppressive or
oncogenic [99,100]. What exactly dictates cellular responsiveness, ie, growth arrest vs. EMT, to TGF-β is
poorly understood. One proposed mechanism was discussed earlier in the anoikis section, where cell-cell
contacts and epithelial polarity complexes sequestered Smad 3 in the cytoplasm [54]. However, the effect of
Smad cytoplasmic sequestration would be to inhibit its transactivation of all target genes including ZEB1. Why
and when TGF-β/Smad3 activates ZEB1 expression and EMT must depend on other co-factors, which modulate
Smad 3 nuclear function and/or repress ZEB1 expression. Such a factor remained un-identified until the present
work.
A “permissive environment” for TGF-β induced EMT can be established in cell culture by modifying
the culture conditions to stimulate various micro environmental cues, these include Wnt, FGF2, TNF-α,
EGF(R), mechanotransduction from extracellular matrix, or factors in the “senescent cell secretory phenotype”
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(SASP) [101-104,105{Scheel #2817]. How these secondary stimuli enhance the EMT response to TGF-β is
unclear. Identifying pathways that these stimuli converge upon and then testing them for their effect on EMT
would be a potentially productive research strategy.
EMT inhibitory factors
BMPs are functional antagonists of TGF-β induced EMT that activate Smads 1/5 compete with Smad
2/3 for the limited pool of Smad4. MET induced by BMP7 has been reported and BMP extracellular
antagonists gremlin and chordin enhance TGF-β induced EMT. The effects of BMPs can be mimicked by
TGFβR2 inhibitors [9,106,107]. Thus, by antagonizing the TGF-β pathway, BMPs represent the only known
natural extracellular stimuli which induce MET, but the underlying mechanisms of this are largely unknown.
The mir200 family of micro RNAs are negative regulators of EMT, which function by directly inhibiting
ZEB1 and ZEB2 translation. Interestingly, ZEB1 and ZEB2 are repressors of mir200 promoters creating a loop
of negative regulation between ZEBs and mir200s. [87,98,108-111]
Epithelial specific mRNA splicing factors ESRP1/2 were recently discovered and they function to
influence the generation of splicoforms of genes that are unique to epithelial cells. Loss of ESRP associated
with EMT leads to mesenchymal splicoform production. Knockdown of ESRP1 induced mesenchymal
properties including up-regulation of vimentin and fibronectin and loss cell polarity. E-cadherin protein was not
down regulated, however, it failed to localize properly to cell junctions, rendering it in active. These data show
that the epithelial gene splicing program influences cellular phenotype; however the splicoforms responsible for
this effect remain to be determined. [112] [113] These are the major negative regulators of EMT: BMPs,
mir200s, and ESRP; what is clearly a knowledge gap in the EMT field are the transcription factors that prevent
EMT/induce MET, and a gene with these novel properties will be described here.
Grainyhead transcription factors
13

Drosophila grainyhead
Grainyhead(aka NTF-1) is a transcription factor expressed in drosophila whose name originated from the
observation that its mutation in flies produced anatomically misshaped (or grainy)heads. It is critical for
processes such as wound healing, epidermal barrier formation, and wing hair polarity (planar cell polarity)[114116]. The domain structure of GRH includes an N-terminal transactivation domain (similar to that of SP1), a
DNA binding domain unique to grainyhead family factors, and a C terminal dimerization domain. [117] [118]
Drosophila grh is known for its transactivation mediated by direct recruitment of the core TAF/TFIID
transcriptional machinery to specific promoters[119]; targets include stit and ddc both essential genes involved
in epidermal integrity.[120,121]. GRH can also repress transcription accomplished by either competing with
co-activators for promoter binding or by recruiting polycomb-repressor complex via direct binding to dring (a
PRC compontent)[122-124]. The mechanisms that dictate the various effects of GRH on target genes are not
understood. GRH can be activated by Erk phosphorylation [120], and perhaps, it represses otherwise; or
repression vs. activation could speculatively depend on whether GRH is binding to the promoter as a monomer
or dimer, ie, whether there are one or two putative binding sites in the target promoter.
Mammalian grainyheads
Three homologues of dGRH are expressed in mammals: GRH-like-1,2,3. Their domain structures also include
the TA, DNA binding and dimerization domains. Despite their high homology with dGRH and each other, the
3 GRHL proteins exhibit distinct tissue expression patterns in both development and in adult tissues.[125,126].
And, while they share some common target genes, they also have unique ones and knockout mice for each gene
exhibit distinct phenotypes. GRHL1 null mice are viable but display delayed hair growth and eventual hair loss
attributed to deficient expression of its direct target desmosomal cadherin 1 (DSG-1)[127]. GRHL2 and 3
homozygous null mice are early embryonic lethal due to neural tube defects [16] but crossing their
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heterozygotes reveals a redundant function of the two in wound healing dependent in part on their direct
activation of the Rho-GEF-19 promoter[128]; Rho-GEF-19 is essential for the planar cell polarity dependent
directed epithelial sheet migration during wound healing[129-131] . Neither GRHL2 nor 3 activate DSG-1 and
GRHL1 fails to activate Rho-GEF-19. Furthermore, GRHL3 is essential and GRHL2 is dispensable for
epidermal barrier formation due to unique activation of the protein cross-linking enzyme, transglutaminase 1, by
GRHL3[128]. GRHL mediated repression of genes is yet to be reported in mammalian tissues.
In two separate, unbiased in-vivo screens, GRHL2 was identified as an activator of epithelial cell-cell adhesion
and was shown to directly activate the E-cadherin and claudin-4 promoters [14,15]. GRHL1 and 3 were not
tested for redundancy in these contexts. In the context of cancer, only GRHL3 has been mechanistically studied
to date. Two groups have shown a model where GRHL3 is a direct activator of the tumor suppressor, PTEN
and a repressor of the onco-mir-21 gene. This model was proposed to explain the phenotype of GRHL3
conditional deletion in the epidermis resulting in squamous cell carcinoma formation and identifies it as a tumor
suppressor gene. [132,133]
Therefore the mammalian grainyhead family of transcription factors are key players in embryonic development,
wound healing, epidermal integrity, cell polarity, and epithelial cell-cell adhesion, all consistent with the known
functions of the well characterized drosophila grh gene. Tumor suppressive role of GRHL3 in SCC brings into
question the roles of the other two family members in cancer. Base on the epithelial-mesenchymal plasticity
observed during wound healing dependent on TGF-β, the regulation of wound healing by GRHL2 and the
activation of epithelial genes by GRHL2 we hypothesized that GRHL2 was a novel transcriptional regulator of
EMT/MET. The next two chapters of this thesis will show that GRHL2 is a potent inhibitor of EMT and can
induce MET. This effect is due to a direct repression of the ZEB1 promoter by GRHL2. GRHL2 also
suppressed TGF-β/Smad dependent transactivation. In-vivo, GRHL2 was down-regulated in human claudinlow breast cancer, renal cell carcinoma, recurrent tumors in mice and it suppressed tumorigenicity in xenograft
15

assays. In experimental systems, GRHL2 enhanced anoikis, suppressed anchorage-independentmammosphere-growth, invasion and sensitivity to chemo-therapeutics. Micro-environmental factors Wnt and
TGF-β collaborated to down-regulate GRHL2 and this was surprisingly dependent on direct repression by
ZEB1. Therefore this thesis has established that GRHL2 is a tumor suppressor gene that engages in a reciprocal
negative repression loop with ZEB1, which regulates EMT and tumorigenicity.
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Abstract
Grainyhead genes are involved in wound healing and developmental neural tube closure. In light of the high
degree of similarity between the epithelial-mesenchymal transitions (EMT) occurring in wound healing
processes and the cancer stem cell-like compartment of tumors, including TGF-β-dependence, we investigated
the role of the Grainyhead gene, Grainyhead-Like-2 (GRHL2) in oncogenic EMT. GRHL2 was down-regulated
specifically in the claudin-low subclass breast tumors and in basal-B subclass breast cancer cell lines. GRHL2
suppressed TGF-β-induced, Twist-induced or spontaneous EMT, enhanced anoikis-sensitivity, and suppressed
mammosphere generation in mammary epithelial cells. These effects were mediated in part by suppression of
ZEB1 expression via direct repression of the ZEB1 promoter. GRHL2 also inhibited Smad-mediated
transcription and it upregulated mir200b/c as well as the TGF-β receptor antagonist, BMP2. Lastly, ectopic
expression of GRHL2 in MDA-MB-231 breast cancer cells triggered a mesenchymal-to-epithelial transition and
restored sensitivity to anoikis. Taken together, our findings define a major role for GRHL2 in the suppression
of oncogenic EMT in breast cancer cells.

24

INTRODUCTION
The oncogenic EMT is a transcriptional re-programming event that endows restricted subclasses of tumor cells
with enhanced metastatic and stem cell-like properties. These properties include increased migration/invasion,
chemo- and radiation-resistance, anoikis-resistance and extraordinary tumor initiation frequency, a cancer stem
cell-like capability (1, 2). In breast cancer, two subclasses of tumors, “claudin-low” and “metaplastic”, exhibit
frank EMT-like gene expression signatures. These are among the most aggressive and least treatmentresponsive tumors (3).
In general, TGF-β signaling can either promote or suppress tumorigenicity and progression (4, 5). It can
suppress tumors through Smad-mediated induction of cyclin dependent kinase-inhibitor genes such as p15, and
inactivating mutations in this pathway occur in certain tumors. In other contexts, however, TGF-β can promote
tumor progression by supporting oncogenic EMT induction, through both transcriptional and nontranscriptional mechanisms. For example, in claudin-low and metaplastic mammary tumors -- as well as in the
stem cell-like CD44high/CD24low tumor cell subpopulation fractionated from breast tumors of other subclasses -TGF-β pathway components are strikingly up-regulated and, indeed, TGF−β receptor kinase inhibitors partially
revert the EMT-related gene expression profile (3, 6). This indicates a pro-tumorigenic role of the TGFβ pathway in this context.
Cell culture models confirm these conclusions. An extensively characterized SV40 large T/hTERTimmortalized mammary epithelial cell line, HMLE, exhibits spontaneous EMT in a subpopulation of
CD44high/CD24low cells (7). This EMT is accompanied by up-regulation of autocrine TGF-β signaling, mainly
through down-regulation of antagonists such as BMP2/4. Reversion to an epithelial phenotype could be
achieved by inhibition of this signaling pathway. Moreover, even Twist-induced EMT in this system was
partially dependent upon autocrine TGF-β signaling, demonstrating its functional significance in multiple
contexts.

25

The similarities between oncogenic and wound-healing-related EMT, including TGF-β-dependence,
have been documented (8-10). In this light, we hypothesized that perhaps other “dedicated” wound-healing
genes might prove important in oncogenic EMT. Grainyhead family genes have been shown to play an
important role in wound-healing, epidermal integrity and the mechanistically related process of embryonic
neural tube closure (11-14). Relevant, albeit limited, Grainyhead family target genes identified so far include
E-cadherin, claudin-4, desmoglein-1, transglutaminase-1, rho-GEF19, several Zelda-target genes expressed
during the maternal-zygotic transition in Drosophila, and telomerase (11, 12, 14-17). With regard to cancer,
GRHL2 gene amplification has been noted in several tumor types, including breast cancer, and suppressed
death receptor expression, conferring resistance to apoptosis mediated by the corresponding ligands, indicating
that GRHL2 was a potential oncogene (18). On the other hand, GRHL3 was recently shown to suppress
squamous cell carcinoma, due to its activation of PTEN expression (19).
Inspired by its role in wound-healing, we hypothesized and report here that GRHL2 suppressed EMT
mediated by the TGF-β signaling pathway. Consistent with this effect, GRHL2 was down-regulated
specifically in EMT-dependent mammary tumors (claudin-low, metaplastic) and cell lines (basal B). ZEB1 was
found to be required for EMT and was a direct target for repression by GRHL2. GRHL2 also enhanced anoikissensitivity. These data suggest an EMT-suppressive function of GRHL2 that is down-regulated in the context
of TGF-β/EMT-driven tumor types.
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MATERIALS AND METHODS
Cell lines
HMLE, HMLE+twist-ER, and HMLE+Ras cells (HMLER) were generous contributions from R. Weinberg
(The Whitehead Institute). HMLE and HMLE+Twist-ER were grown in a 1:1 mixture of MEGM (Lonza) and
[DME/F12(Gibco)+5% horse serum+1X penicillin-streptomycin-glutamine (PSG) +10 µg/ml insulin, 10 ng/ml
EGF, 0.5 µg/ml hydrocortisone], where indicated, 4-hydroxytamixofen (10ng/ml) was added to the
HMLE+Twist-ER cells to activate the Twist-ER protein. HMLER cells were grown in MEGM. MDA-MB231LN were provided by E. Pugacheva (West Virginia University) and were grown in Advanced DMEM
(Invitrogen)+10% fetal bovine serum+1X penicillin-streptomycin-glutamine (PSG).

Generation of stable cell lines by retroviral transduction.
Human GRHL2 was amplified from a template purchased from Open Biosystems (MHS4426-99625903) and
subcloned by standard molecular biology methods into the pMIG or MSCV-IRES-puro retrovirus (Addgene;
XhoI site). Retroviruses were packaged and amplified in GP2+293T cells by transfection of 4.5 µg of retroviral
plasmid and 2.5 µg of pCMV-VSV-G per 60mm2 dish of cells, using Mirus TransIT reagent. Viral supernatants
were collected forty-eight hours later, filtered through 0.45 micron filters (Whatman) and 0.6 ml of supernatant
was used to infect one well of a 6-well dish of target cells by centrifugation at 1400 rpm for one hour followed
by 6 hour to overnight incubation. Infected cells were either selected for puromycin (2 µg/ml for HMLE, 0.5
µg/ml for MDA-MB-231) or flow-sorted for GFP, followed by western blot analysis to verify expression.

Generation of stable cell knockdown cell lines by lentiviral transduction, and transient knockdown (siRNA).
GRHL2, ZEB1 and scrambled control shRNAs were purchased from Open Biosystems in the pGIPZ vector.
(Catalogue numbers: shGRHL2a: RHS4430-99291384; shGRHL2b: RHS4430-99614394 . shZEB1a:
V3LHS_356186 and shZEB1b: 3 V3LHS_356187; the latter were also sub-cloned into vector pTRIPz using
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Mlu1/Xho fragments). SiZEB1 Smartpool was from Dharmacon catalogue number (L-006564-01-0005) and
was transfected transiently using Lipofectamine RNAi-max (Invitrogen).

Mammosphere assay
Mammospheres were seeded at 1x104 cells/ well of a 6 well Ultra Low Cluster Plate (Corning) and grown for 7
to 10 days in the appropriate growth media + 0.5% methylcellulose (MC). Wells were fed every third day with
1ml media+MC. Total mammospheres/well were counted and the size cutoff was set at 150mm in diameter;
the same cells were plated at 2x105 cells/well of a 6-well plate and the number of cells was counted each day for
4 days, to measure normal growth rate. Error bars represent the standard deviation of replicates.
Anoikis assays
Cells were dissociated using TrypLE Express (Invitrogen), counted and a fixed amount (1x105 to 2x105
cells/well of a 6-well Ultra-Low Attachment Cluster Dish (Costar) were suspended in normal growth media
+0.5%MC for the indicated for 6 to 24 hours to induce anoikis. For Cell Death ELISA (CDE) analysis of
apoptotic DNA fragmentation, the cells were collected in 3 volumes of media and then spun down at 1500rpm
for 3min. The pellet was then washed with D-PBS (Invitrogen) transferred to a microfuge tube, pelleted at
7,000 rpm for 15 seconds and lysed in PBS+0.5% Triton X 100+10mM EDTA (Note: the lysis buffer with the
Cell Death ELISA kit from Roche was found to lyse cells inadequately). Lysates were incubated on ice for
fifteen minutes with occasional mixing, and then centrifuged at 13,000rpm for 12 minutes. The supernatants
were subjected to the CDE according to the manual provided with the kit (Roche). Alternatively, percentage cell
death was determined by a trypan blue exclusion assay, wherein cells were suspended in same manner but
collected and re-suspended in Accumax (Innovative Cell Technology) to ensure a single cell suspension. After
brief incubation (2-3min) trypan blue was added to this solution and the % dead cells were immediately counted
on a hemacytometer. All samples were analyzed in either duplicate or triplicate, and time-zero cell death values
were subtracted from the data presented here.
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Three dimensional culture
3D Matrigel culture methods were adapted from :(20). To summarize, 2.5x103 cells/well were seeded onto 8
well chamber slides (Labtek) where 45ul Matrigel(Trevigen) had been evenly distributed. The cells were
overlaid with the appropriate growth media (see above) +2.5% matrigel. After 6 days in culture 3D
migration/invasion was quantified by counting the number of structures which had formed protrusions vs. those
which grew as lobular structures defined by their contact with matrix. (see images for clarification). At least
200 structures were counted per experiment; error bars represent the standard deviation across three samples.

Microarray methods
RNA isolated by RNeasy Plus kit (Qiagen) was quantified using Nanodrop (Fisher Scientific). The RNA
quality was check on Bioanalyzer (Agilent). Two hundred fifty nanograms of each RNA sample with an RIN
value greater than seven was processed using the Ambion WT Expression Kit according to the manufacturer’s
instructions. The typical yield from the reaction was 6-9 micrograms of cDNA. The required amount of cDNA
(5.5 micrograms) was processed for fragmentation and biotin labeling using the Gene Chip WT Terminal
Labeling Kit (Affymetrix). The efficiency of fragmentation reaction was checked via Agilent Bioanalyzer. The
entire reaction of fragmented and biotin-labeled cDNA (50 microliters) with added hybridization controls was
hybridized to the human GeneChip 1.0 ST Exon Arrays (Affymetrix) at 45°C for 17 hours in GeneChip
Hybridization Oven 640 (Affymetrix) . Human GeneChip 1.0 ST Exon Arrays were stained using FS
450_0001 protocol in Affymetrix GeneChip Fluidics Station 450. Briefly: Biotin-labeled cDNA was reacted
using two rounds of washes with a solution containing a streptavidin-phycoerythrin complex, with an
intermediate treatment of biotin-labeled anti-streptadvidin antibody to amplify the signal. Phycoerythrin
labeling was detected within the Affymetrix GeneChip Scanner 3000 7G plus using 532 nm light and detected
by a photomultiplier tube. Expression Consol software (Affymetrix) was used to check quality controls of
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hybridized chips. All chips that passed quality controls were RMA normalized using Expression Console
software. The microarray data were deposited into the NCBI GEO database as accession number GSE36081.
To examine the extent to which GRHL2 affects the propensity to undergo Epithelial to Mesenchymal Transition
(EMT), we compared the relative expression of genes in an identified EMT signature (21) to the relative
expression of genes in cells with constitutive GRHL2 expression. Specifically, we obtained the expression
profile of the 251 Core EMT signature genes from table S1 of (21) and computed the mean log ratio of the
relative expression. We restricted the genes to those which appeared on our array platform and computed the
Pearson Correlation coefficient of those genes to the log expression ratio of GRHL2-regulated genes compared
to the control.

Reporter assays
HMLE were transiently transfected using Lipofectamine 2000 (Invitrogen) at a 1µg DNA:2ul Lipofectamine
ratio. 1.5 µg DNA/well of a 12 well was the maximum amount of DNA found to be tolerable. Transfection
mixtures were incubated for 20 minutes in 200 µl Opti-MEM (Invitrogen) and then added to the cells in normal
growth media lacking antibiotics. Cells were incubated for 4h then re-fed with normal growth media. Lysates
were made by washing the cells once with PBS then lysing in 1x Cell Culture Lysis Buffer (Promega). Lysates
were centrifuged at 13, 000 rpm for 10 minutes and the supernatants were assayed for luciferase and βgalactosidase activity as internal control. Luciferase assay reagent was obtained from Promega and the βgalactosidase 2X assay reagent was 200 mM sodium phosphate (pH 7.3), 2mM MgCl2, 100 mM 2mercaptoethanol, and 1.33 mg/ml o-nitrophenylgalactoside. The Smad reporter construct 3TP-Lux was from
Addgene. The ZEB1 promoter-luciferase construct in pGL3 (22) was kindly provided by Antonio Garcia de
Herreros (Barcelona, Spain). CMV-LacZ or TK-LacZ were used as internal controls. The GRHL2 clone was
purchased from Open biosystems, cat # MHS4426-99625903, and the coding sequence was cloned into the
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XhoI site of pcDNA3.1+ . Sub-fragments of the ZEB1 promoter were generated and cloned into pGL3promoter (MluI-BglII) using the following primers: Fragment 1: ZPfr1-f:Ttaat ACGCGT
CCTTAAGGTCCTGCACGGCG, ZPfr1-r: tatat agatct AAGTTCCGCTTGCCAGCAGC; Fragment 2:
ZPfr2-f: TtaatACGCGT CTAGCCTCTCTTTCAATCCA, ZPfr2-r:
tatatagatctTCCGCCCCCCGCACCCCGGGGC; Fragment 3: ZPfr3-f:
TtaatACGCGTCACGCGAGGCGTGGGACTGA, ZPfr3-r: tatat agatct GGATGCCGGGAAACCGTAGG;
Fragment 4: ZPfr4-f: Ttaat ACGCGT GCCTCCCTCTCCCCACCACA,
ZPfr4-r: tatat agatct ACCGCACCTGGTTTACGACA; Fragment 5: ZPfr5-f: TtaatACGCGT
GCGGACCGGGTGTGGGAGGC, ZPfr5-r: tatat agatct TACCTGACCCGCGCAGCCCG;
Fragment 6: ZPfr6-f: Ttaat ACGCGT GCCTCTCTCCGGTCGCCGCG,
ZPfr6-r: tatatagatct GGGGCAGGGAGGGATCTGGC, Fragment 7:
ZPfr7-f: Ttaat ACGCGT GGGCAGCCGCGGCGGGTGTG,
ZPfr7-r: tatat agatct ACCGTGGGCACTGCTGAATT.
The primers used to mutate the fragment 4 construct (using Stratagene Quickchange II XL kit) were: Mut-

f:gtaaagccgggagtgtcgtcccacaggtgcggtagatctgcg;Mut-r: cgcagatctaccgcacctgtgggacgacactcccggctttac
Immunofluorescence
For Smad2 localization, TGF-β (5 ng/ml) was added for 6h and the coverslips were fixed with 4%

paraformaldehyde(PFA) in PBS for 10minutes. PFA was quenched with 100mM glycine in PBS. Cells were
permeabilized with 0.2% TX100 in PBS at 4 degrees for 10minutes, washed twice with PBS, and blocked for
one hour in: PBS+10% goat serum+0.1% Tween-20+0.1%BSA. Primary and secondary antibodies were
diluted in blocking buffer. Primary antibodies were as follows: SMAD2, Cell Signaling, rb, 1:200.
Secondary: rb Alexa 555(red), Molecular Probes, 1:1000. Mounting media: Prolong Gold w/ DAPI
(Invitrogen).
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For E-Cadherin, vimentin and GRHL2 the cells were fixed in 100% Methanol at -20oC for at least 1 hour. They
were then washed twice with PBS and blocked as above. Ecadherin, ms, BD, 1:200; Vimentin, rb, Cell
Signalling, 1:200; GRHL2, rb, Sigma, 1:200. Secondaries used were anti-mouse Alexa 555 (red) or anti-rabbit
Alexa 488(green) or A555 (red), (Molecular Probes), diluted 1:1000. Coverslips were mounted in Prolong Gold
as above. Images were produced using the Axiovert 200M microscope, AxioCam MRM camera, and Axio
Vision 4.3.1 software (Zeiss).
CHIP
5 x100mm dishes of 4-OHT-induced HMLE+twist-ER (+GRHL2, in some experiments) were each fixed in
1.2ml 10% electron microscopy grade paraformaldehyde for 10 minutes. Following quenching with glycine,
CHIP was performed exactly as described previously (23) with the following antibodies: (3.3 µg each): GRHL2
(Sigma); Histone H3 (Cell Signaling), or non-immune rabbit IgG (Pierce). CHIP-derived DNA was analyzed by
PCR using the following primer sets:
AAAGTTGGAGGCTCGGCGGC;

ZEBf10:

TTCCGCTTGCCAGCAGCCTC;

GAPDH-f:

ZEBf6: GCGAGGCGTGGGACTGATGG;
CTGCACGGCGATGACCGCT;
ATGGTTGCCACTGGGGATCT;

ZEBr6:
ZEBr10:
GAPDH-r:

TGCCAAAGCCTAGGGGAAGA. For qPCR analysis, CHIP DNAs were analyzed using 2X Power-Sybr
Green Master Mix (Applied Biosystems) and signals were calculated relative to input DNA using the “∆∆-Ct”
method; a correction of 1.5X was applied to adjust for the higher efficiency of GAPDH amplification compared
with ZEB1 amplification obtained in a control reaction using lysates from GRHL2-null cells. The primer set
used was F8: GCCGCCGAGCCTCCAACTTT; R8: TGCTAGGGACCGGGCGGTTT.

Western blotting
SDS-PAGE was conducted using 4-20% gradient Tris Glycine gels, (Invitrogen). Proteins were immobilized
by electophoretically transferring them to a PVDF filter (Immobilon FL, Millipore) in 5% MeOH containing
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Tris-Glycine transfer buffer. Filters were blocked in PBS+5% non-fat milk, primary antibodies were incubated
in PBS+0.1% Tween20+5% non-fat milk, secondaries were incubated in PBS+0.1% Tween20+5%milk+0.01%
SDS. Primaries were typically incubated for 2h to overnight, secondaries were incubated for 1h. Primaries
used were: Ecadherin, ms, BD Biosciences(BD); Vimentin, ms, Santa Cruz Bio-Tech(SCBT); N-Cadherin, ms,
BD; CD44(HCAM), ms, SCBT; ESRP1/2, ms, (Contributed by Russ Carstens, University of Pennsylvania,
Philadelphia, Pa); Actin, ms, Millipore; Akt, rb or ms, Cell Signaling(CS); GRHL2, rb, Sigma; Zeb1, rb, Sigma
or rb, CS; Ankyrin-G, rb, S.M.F. custom generated (23); total-Smad2/3,ms, BD; phospho-Smad2/3, rb, CS;
NF2(merlin), rb, SCBT. Secondary antibodies for chemi-luminescence were either anti-mouse or anti-rabbit,
conjugated to horseradish peroxidase (Biorad) and were used at 1:3000 dilution; western blots were developed
using (ECL-West Pico, Pierce). Fluorescently tagged secondary antibodies were mouse IRDye 800CW or
rabbit IRDye 680LT (Li-Cor) used at 10:000 and detected using the Odyssey Infrared Imaging System (Li-Cor).
Fluorescent images were converted to gray scale.

Other bioinformatics methods
We obtained GRHL2 expression data from NCBI Gene Expression Omnibus (accession number GSE10885
(3)). We compared the log expression of GRHL2 among the tumor types Basal, Claudin, Her2, Luminal, and
Normal. We performed a Tukey HSD test to determine which comparisons among these groups demonstrated
statistically significant differences; family-wise 95% confidence intervals for the log expression were plotted.
Statistical analyses were performed using R version 2.13.1 (www.r-project.org).

RESULTS.

Loss of GRHL2 Expression is Associated with a Mesenchymal Phenotype
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Based on the specific expression of GRHL2 in mouse
epithelia (12-14, 24), we investigated its potential
Figure 1a. Twist downregulates GRHL2. HMLE
cells with tamoxifen-inducible
twist (twist-ER) were induced
with 4-hydroxytamoxifen for
the indicated periods of time
and analyzed for epithelial,
mesenchymal and tumor
intiating cell (CD44) marker
genes.

regulation during EMT. Using HMLE cells that
express a twist-ER fusion -- a previously characterized
Figure 1b. GRHL2 is
down-regulated in the
Mesenchymal SubPopulation (MSP) cells

relative to parental
HMLE cells.

model of inducible EMT (21) -- we analyzed the levels
of GRHL2 over a time-course of twist induction by
tamoxifen and found that, indeed, GRHL2 protein was

Figure 1c. GRHL2 is down-regulated specifically in “basal B” subclass of breast cancer cell lines characterized by Neve, et al.
(42).

down-regulated during EMT with kinetics similar to the loss of
E-cadherin and gain of N-cadherin (Figure 1a). Consistent with
this finding, spontaneous, stable EMT in a subpopulation of
HMLE cells (“Mesenchymal Subpopulation”) obtained by
sorting for CD44high phenotype, described previously (7), also
displayed low GRHL2 expression (figure 1b).
Figure 1d. GRHL2 is down-regulated specifically
in the “claudin-low” subclass of breast cancer cell
lines characterized by Hennessy, et al. (3).
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Figure 1e. GRHL2 is down-regulated specifically in the tumor
initiating/mesenchymal cell subpopulation characterized by Creighton,
et al (25).

Breast cancer cell lines have been classified by
gene expression profiles. One particular subclass,
basal B, was characterized by a mesenchymal
profile. GRHL2 was dramatically down-regulated,
specifically in this subclass (figure 1c).
Analogously, the “claudin-low” subclass of

a

Figure 2a. Ectopic expression of GRHL2 suppresses the
CD44 expression in the spontaneously occurring
mesenchymal subpopulation of HMLE cells (“MSP”).
HMLE+Twist-ER cells (without 4-OHT) infected with
GRHL2 or empty retroviral vector (pMIG) were analyzed
for CD44 expression by FACS.

mammary tumor samples – also characterized by
mesenchymal gene expression profile and poor
prognosis—expressed substantially lower levels

of GRHL2 than other subclasses, which, in fact, showed a modest up-regulation, compared to normal breast
tissue (figure 1d, and see Discussion). GRHL2 was also down-regulated dramatically in a different tumor type
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characterized by EMT, clear cell renal carcinoma (figure S1). Moreover, chemoresistant subpopulations of
primary breast tumor cells obtained after chemotherapy of patients by sorting for CD44high/CD24low marker
expression or mammosphere
generation (25) expressed
decreased levels of GRHL2 as
well (figure 1e).
These data suggested that
GRHL2 loss is a widespread
characteristic of both primary and
cultured tumor cells that have
Figure 2b. GRHL2 reverts MSP cells to an epithelial phenotype. The CD44high
mesenchymal sub-population of HMLE, obtained by flow-sorting of HMLE cells,
were infected with empty vector or GRHL2 and then (top panel) stained for the
indicated proteins by immunofluorescence or (lower panel) probed for epithelial and
mesenchymal marker genes by western blotting.

undergone EMT and acquired a
tumor-initiating phenotype,

informed the hypothesis that GRHL2
down-regulation was functionally
important for EMT.
GRHL2 is an EMT suppressor
The spontaneously occurring,
CD44highCD24low MSP cells within the
Figure 2c. GRHL2 expression in MSP cells restores anoikis-sensitivity (left
panels: top graph represents a DNA fragmentation ELISA assay, lower graph
represents a trypan blue-permeability assay) and reduces mammosphere
(middle panels), without affecting growth rate (right panel).

heterogeneous HMLE cell line are
characterized by EMT, attributed to
autocrine signaling pathway activation

(7). Infection of HMLE cells with a GRHL2 expression construct and selection for the infected cells using a
GFP marker caused the disappearance of the CD44high subpopulation (figure 2a) within a few days after
infection, suggesting a conversion effect rather than selective growth (as demonstrated below).
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To further characterize this phenomenon, we isolated MSP cells from the HMLE cell line by flow sorting and
infected these with the GRHL2 retrovirus. Based on E-cadherin immunofluorescence and western blotting for
epithelial and mesenchymal markers, GRHL2 reverted MSP back to an epithelial phenotype (figure 2b).
Anoikis-resistance and the ability to form mammospheres are key characteristics associated with EMT in
HMLE cells. GRHL2 expression in the MSP cells restored anoikis-sensitivity and reduced mammosphere
formation dramatically, without affecting adherent cell growth (figure 2c).
These data indicated that GRHL2 reverted the spontaneous EMT and accompanying tumor initiating cell
characteristics of MSP cells. To test the effect of GRHL2 in other scenarios of EMT, we expressed it
constitutively in HMLE+Twist-ER cells and in the prototypical EMT-like/triple-negative breast cancer cell line,
MDA-MB-231, where it caused dramatic reversion of EMT and anoikis-resistance in both cases (figures 2d,
2e),

Figure 2d. GRHL2 suppresses Twist-induced
EMT. HMLE+twist-ER expressing either
empty vector or GRHL2 were treated with 4OHT (to activate the twist transgene) for 7
days, and (top panel) photographed to record
morphology. (lower panel): Time course of
changes in epithelial and mesenchymal marker
genes after induction of the twist gene with 4OHT, in cells with or without ectopic GRHL2
expression.

Figure 2e. GRHL2 suppresses EMT and anoikis-resistance in
MDA-MB-231LN cells. MDA-MB-231LN expressing either
empty vector or GRHL2 were analyzed for morphology (phase
contrast microscopy,top left), E-cadherin expression and
localization (immunofluorescence, top right), expression of
epithelial and mesenchymal markers (western blotting, bottom
left), anoikis-sensitivity (DNA fragmentation ELISA (middle)
and adherent growth rate (lower right).

indicating a surprisingly broad specificity for this effect.
37

GRHL2 suppresses TGF-β-induced EMT.
MSP cells and Twist-expressing HMLE cells rely on autocrine TGF-β signaling for their maintenance of
mesenchymal and tumor-initiating properties (7), suggesting that GRHL2 could be suppressing EMT through
this common
pathway. We
confirmed that
twist-mediated
EMT and
acquisition of
anoikis-resistance
were TGF-βdependent by using
LY364947, a
Figure 3a. GRHL2 knockdown permits HMLE cells to undergo TGF-β-induced EMT.
HMLE+twist-ER cells (no 4-OHT) with two distinct GRHL2 shRNAs or a scrambled control
shRNA were exposed to TGF-β for two weeks prior to analysis for cell morphology (top left),
E-cadherin expression/localization (immunofluorescence, top right) or mammosphere
generation (graph, lower right). Epithelial and mesenchymal markers were also analyzed at
the indicated times of TGF-β treatment (western blot, lower left).

specific inhibitor of
the TGF-βR1
kinase activity

(figure S2). Because this inhibitor mimicked the effects of ectopic GRHL2 in some respects, we tested the
effect of GRHL2 on TGF-β-induced EMT. TGF-β alone was previously reported to be insufficient for EMT
induction in HMLE, a process requiring activation of multiple pathways (7). When GRHL2 was partially
depleted by two distinct shRNAs, TGF-β alone induced EMT more efficiently than in cells with control shRNA
(figure 3a). GRHL2 knockdown facilitated several activities of TGF-β: induction of a mesenchymal
morphology, down-regulation of epithelial specific genes (E-cadherin, ESRP1 and ankyrin-G – an epithelial
cytoskeletal protein that regulates anoikis (23)), and up-regulation of vimentin as well as the tumor initiating
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cell marker, CD44S; surprisingly, TGF-β induced N-cadherin partly independently of GRHL2 expression.
Coincident with this facilitation of EMT, GRHL2
knockdown also permitted TGF-β to confer a
mammosphere-generating, anoikis-resistant state
(figure 3a,b). GRHL2 also suppressed another feature
of EMT, the formation of large protrusive structures
during the growth of colonies in three-dimensional
matrigel culture, indicative of invasive potential
(figure S3).
Figure 3b. GRHL2 suppresses the ability of TGF-β to confer
anoikis-resistance. The cell lines described above were assayed
for anoikis by DNA fragmentation after two weeks incubation
with or without TGF-β.

These results suggested that signaling downstream of

Figure 3c. GRHL2 inhibits Smad-mediated transcription. (left panel): Effect of stable GRHL2 knockdown on activity of a
Smad-responsive reporter construct (3TP-lux) was determined by luciferase assays of transiently transfected HMLE+twist-ER
cells (no 4-OHT) expressing either scrambled or GRHL2a shRNA that were treated with TGF-β for sixteen hours prior to lysis;
values are luciferase activity normalized to an internal co-transfected β-galactosidase control. (lower panel): Effect of stable
GRHL2 knockdown on induction of TGF-β/Smad target genes, CTGF and ZEB1, by exogenous TGF-β, determined by qRTPCR. (top panel): No effect of GRHL2 on phosphorylation of Smad2/3. MSP cells expressing empty vector or GRHL2 were
treated with the indicated concentrations of TGF-β for 24h and analyzed for total and phospho-smad2/3. (right panel): No effect
of GRHL2 on nuclear translocation of Smad2. The GRHL2 knockdown or control cells described in part a were treated with
TGF-β for six hours and analyzed for Smad2 localization by immunofluorescence.
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the TGF-β receptor might be suppressed by GRHL2. We focused on Smad-mediated transcription, as it plays
an important, although not exclusive role in
the response to exogenous TGF-β-mediated
EMT (4). Using a well-characterized
reporter assay (3TP-lux; (4)), GRHL2
knockdown stimulated TGF-β/Smad
mediated transcription by ~4.6X relative to
control cells (figure 3c). Correspondingly,
GRHL2 knockdown promoted the
Figure 3d. GRHL2 knockdown induces EMT in HMLE cells with Ras
(HMLER). HMLER expressing two distinct GRHL2 shRNAs or
scrambled shRNA control were imaged using phase contrast microscopy
(top), immunoblotted for epithelial and mesenchymal markers (right) or
assayed for anoikis (trypan blue exclusion, left panel).

induction of the TGF-β/Smad target genes,

CTGF (26) and ZEB1 (27), by exogenous
TGF-β. Surprisingly, there was no
discernable effect of GRHL2 on either the
phosphorylation or nuclear translocation of
Smad2, suggesting that other mechanisms
of inhibition were operative (see
Discussion). These results indicated that
Figure 3e. GRHL2 up-regulates BMP2. RT-PCR was performed on RNAs
from HMLE+Twist-ER cell lines with or without constitutive GRHL2
expression (induced with 4-OHT), using the indicated primer sets.

GRHL2 inhibited Smad-mediated
transcription in response to exogenous

TGF-β.
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In HMLE
cells
expressing
low levels of
activated Kras,
(HMLER),
Figure 4a. HMLE+Twist-ER expressing either empty
vector or GRHL2 were induced with 4-OHT for 17 days;
four days following removal, RNAs were isolated and
compared by microarray profiling. Gene changes due to
GRHL2 were compared to those due to Twist in the same
cell line; a regression plot of this comparison is shown.

GRHL2
Figure 4b. GRHL2 up-regulates mir-200b/c.
RNAs from HMLE or HMLER cells
expressing GRHL2 or control shRNAs were
compared for the indicated mir-200 transcripts
by RT-PCR.

knockdown
sufficed to

induce EMT --i.e., even
without exogenous TGF−β-based on the criteria used above
(Figure 3d). This EMT was
clearly dependent upon
autocrine TGF-β signaling, in
that LY364947 reversed it
(Figure S4). The TGF-β
Figure 4c. GRHL2 represses the ZEB1 promoter. (left panel): MSP cells were cotransfected with a ZEB1 promoter-luciferase reporter construct, with the indicated input
amounts of GRHL2 expression vector or equal amounts of empty vector. Values
represent the relative luciferase activity normalized to an internal β-galactosidase control;
(right panel): HMLE+Twist-ER cells (no 4-OHT) with stable GRHL2 knockdown or
control (scrambled) knockdown were assayed for luciferase activity after transient
transfection of the ZEB1 promoter.

signaling antagonists BMP2
and-4 were previously shown to
be down-regulated in MSP cells
relative to normal HMLE,
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which promoted autocrine TGF-β signaling (7). Interestingly, BMP2 expression was activated by GRHL2
(figure 3e), consistent with the idea that GRHL2 suppressed not only TGF-β signaling in response to exogenous
ligands but also (by comparison with reported data on the same cell lines (7)) autocrine signaling.

GRHL2 Represses ZEB-1 expression
Suppression of EMT by GRHL2 could occur by a diversity of mechanisms. To elucidate one or more of these
in an unbiased manner, we performed a microarray-based gene expression profiling comparing the HMLETwist cells with or without GRHL2 expression. This analysis revealed that genes regulated by GRHL2 (GEO
database accession number GSE36081) correlated negatively (R=-.7508) with genes regulated during EMT (by
multiple transcription factors) in the HMLE system, validating the EMT-suppressive effect of GRHL2 (Figure
4a). The genes regulated by GRHL2 included markers of epithelial vs. mesenchymal phenotypes, several of
which were ZEB1 target genes; transcription factors implicated in the control of EMT were also noted.

Interestingly, one of the major down-regulated GRHL2 target genes was the E-cadherin repressor/EMT inducer
ZEB1, as shown by RT-PCR (figure 3e) and Western blotting in MSP cells (figure 2b), MDA-MB-231 cells
(figure 2e), HMLE+shGRHL2 cells with TGF-β (figure 3a), HMLER+shGRHL2 cells (figure 3d) and
HMLE+Twist-ER cells (figure 2d). Functional consequences of ZEB1 down-regulation (28) such as the upregulation of mir-200b/c (figure 4b) and ESRP1 (figure 3e) were also evident . The down-regulation of ZEB1
by GRHL2 was investigated further as a potential mechanism for suppression of EMT.

42

To determine
whether the ZEB1
gene could be a
direct target for
GRHL2, we cotransfected the
previously
Figure 4d. Identification of a ZEB1 promoter fragment that is GRHL2-sensitive, and contains a
GRHL2 consensus binding site. (left panel): Fragments (~200bp) spanning the 1 kb ZEB1 promoter
were assayed for transcriptional activity in the presence or absence of co-transfected GRHL2. The
fragment 1-4 sequence and predicted GRHL2 binding site are shown. (right panel): Fragment 4
containing wild-type or mutant versions of the predicted GRHL2 binding site were assayed for
repression by co-transfected GRHL2.

characterized ZEB1
promoter (22)
together with

GRHL2 into the MSP cells (which express low endogenous
GRHL2). This revealed a marked repression of the ZEB1
promoter by GRHL2, as did the converse experiment, transfection
of the ZEB1 promoter into cells with or without knockdown of
endogenous GRHL2 (figure 4c).

Inspection of the ~1 kb of promoter sequence that was GRHL2Figure 4e. GRHL2 protein interacts with the
ZEB1 promoter. Chromatin from
HMLE+Twist-ER+GRHL2 (upper panel) or
MDA-MB-231+GRHL2 (lower panel) was
immunoprecipitated with GRHL2, histone
H3 or non-immune antibody and analyzed by
gel-based PCR or qPCR, using the indicated
CHIP primers.

responsive revealed several potential binding sites for grainyhead
proteins. We tested ~200bp nested fragments of the ZEB1
upstream region, in the context of an SV40 promoter, for
repression by GRHL2, and identified one fragment (fragment 4)

that was highly repressed. This fragment contained a consensus GRHL2 binding site and also carried a strong
enhancer; the repression by GRHL2 was completely eliminated by a four-base mutation of this consensus site
(figure 4d). To determine whether the ZEB1 promoter was a direct target for repression by GRHL2, CHIP
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analysis was performed, demonstrating a strong enrichment of PCR signal using GRHL2 antibody, with respect
to non-immune IgG or a primer set (using GRHL2 antibody) representing an unrelated region of the genome
(figure 4e). These results indicated that GRHL2 repressed ZEB1 expression and interacted directly with the
ZEB1 promoter.

Suppression of ZEB1 is critical for the suppression of EMT by GRHL2.

ZEB1 plays a critical
role in EMT in
response to various
stimuli including
TGF-β (29-33),
informing the
hypothesis that
GRHL2 suppressed
EMT, at least in part,
by repressing ZEB1
expression. To test
Figure 5a. ZEB1 restores EMT capability and anoikis-resistance in cells that express GRHL2
constitutively. HMLE+twist-ER with or without constitutive GRHL2 expression and with empty
vector or ectopic ZEB1 expression vector were treated with 4OHT and then analyzed for anoikis
(DNA fragmentation ELISA, top left); E-cadherin expression/localization (immunofluorescence, top
right), cell morphology (phase contrast, lower left) and expression of epithelial and mesenchymal
markers (western blot, lower right).

this, ZEB1 was
expressed
ectopically, using a

doxycycline-inducible promoter, in the HMLE+twistER+GRHL2 cells. By the criteria of morphology,
expression of epithelial and mesenchymal markers, and anoikis-resistance, ZEB1 restored EMT that had
previously been blocked by GRHL2 expression (figure 5a). Analogous effects of ZEB1 expression were also
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observed in MSP cells that had been
reverted to an epithelial phenotype by
stable GRHL2 expression (figure S5).
Conversely, in the HMLE cells where
GRHL2 knockdown predisposed the cells
toward
TGF-β induced EMT, ZEB1 knockdown
blocked this induction (Figure 5b).
Figure 5b. ZEB1 knockdown prevents TGF-β-induced EMT in GRHL2
knockdown cells. HMLE+twistER (without 4OHT) expressing shGRHL2a
were transfected with either non-targeting siRNA or ZEB1 siRNA prior to
incubation with or without TGF-β Cells were analyzed for epithelial and
mesenchymal markers (western blot, top panel), morphology (phase contrast,
lower left panel), or E-cadherin expression/localization
(immunoflourescence, lower right).

Similarly, EMT that was induced by
GRHL2 knockdown in HMLER cells
was reversed by ZEB1 knockdown
(figure S6). These results indicated that

the repression of ZEB1 was a key mechanism by which GRHL2 suppressed EMT.

DISCUSSION.

Mammalian GRHL2 is a transcription factor that plays important role in epidermal junctions, in part due to
activation of target genes including claudin-4 and E-cadherin. Consistent with this role, the Drosophila
Grainyhead gene is among the first transcription factors utilized in the maternal to zygotic transition (MZT)
during embryonic development (16), and the three mammalian Grainyhead genes are critical for embryonic and
adult wound healing (11-14). In light of the fact that wound-healing is orchestrated in part by TGF-β signaling
(9), the suppressive effect of GRHL2 on this pathway suggests that GRHL2 may contribute to the resolution
phase of wound-healing, wherein transient EMT-like cell conversions in keratinocytes are instructed to reverse.

45

The suppressive effect of GRHL2 on oncogenic EMT may be understood by analogy to this function, given the
similarities between the two contexts of EMT (8).

The significance of mammalian Grainyhead proteins in cancer is emerging. GRHL3 was recently shown to
function as a tumor suppressor in squamous cell carcinoma, acting, at least in part, as a direct activator of PTEN
expression (19); EMT-related issues were not examined, however. The GRHL2 gene shows frequent
amplification in unclassified breast tumor samples, and has been proposed as a potential oncogene in breast
cancer, due, in part, to its suppression of death receptor expression (18). Consistent with this, modest upregulation of GRHL2 mRNA was observed in luminal A, B and HER2-positive tumor types (figure 1d)
(although it is unclear whether this is an artifactual result of expansion of the epithelial cell compartment
relative to normal mammary gland during tumor outgrowth). By contrast, our results show that GRHL2 is
down-regulated in EMT models and EMT-driven tumor subclasses, and that it suppresses TGF-β-induced ZEB1
expression; in light of the established pro-tumorigenic potential of ZEB1, this result predicts that GRHL2 will
specifically suppress EMT-like tumors (34, 35).

These results can be reconciled in light of the diametrically opposed, context-dependent effects of TGF-β:
growth arrest and tumor suppression in certain tumors vs. tumor promotion in others (4). In breast cancer,
fewer than 10% of patients have tumor types (claudin-low, metaplastic) in which EMT/TGF-β contributes
critically to tumor progression, while in the majority of tumors (other basal, luminal A,B and HER2-positive
subclasses) – which most transgenic mouse models emulate—TGF-β is tumor-suppressive
The results here indicate that GRHL2 interferes with the response to TGF-β by at least two mechanisms,
interference with Smad2/3 mediated transcriptional activation and direct repression of the ZEB1 promoter
(diagrammed in figure 6). Consistent with previous observations in other systems (28, 37), ZEB1 was required
for EMT in response to Twist, TGF-β and spontaneous conversion. GRHL2 also up-regulated mir-200b/c,
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consistent with a critical role of the established ZEB1/mir-200 feed-forward regulatory loop in EMT (28). The
precise mechanism by which GRHL2 represses the ZEB1 promoter may relate to Grainyhead proteins’ ability
to repress transcription, by recruiting polycomb repression complex components or by interfering with the
binding of a transactivator (16, 38).

The mechanism by which GRHL2 inhibits Smad-mediated transcription is unresolved at present. Previous
work has shown that ZEB1 protein can bind to the Smad2/3 complex, enhancing transactivation (39); our
preliminary observations indicated that this mechanism did not apply in our system. Smad2/3 nuclear vs.
cytoplasmic localization is regulated by phosphorylation as well as signaling from the Crumbs polarity complex
through Hippo pathway components (26). These mechanisms were, however, unlikely to explain the
suppression by GRHL2, because Smad phosphorylation and nuclear translocation were not apparently affected.
Other nuclear proteins that affect Smad2/3 transactivation, such as TGIF, Ski, and Sno (4), remain to be tested
in the context of GRHL2.

TGF-β-induced EMT is a highly restricted
phenomenon in cell culture models, occurring
in only a small number of epithelial cell lines
(40). In fact, we observed that the mouse
mammary epithelial cell line NMuMg,
commonly used to study this phenomenon,
Figure 6. EMT is induced by the combination of TGF-β with
other micro-environmental factors, and requires the activation of
ZEB1 plus other target genes. Microenvironmental factors (Wnt,
NF-kb agonists?) up-regulate Twist and Snail genes, which
down-regulate GRHL2. This down-regulation alleviates the
repression of the ZEB1 promoter, permitting TGF-β (partly,
through Twist and Snail themselves) to activate ZEB1
expression. The down-regulation of GRHL2 also enhances
Smad-mediated transactivation of TGF-β target genes, which,
together with ZEB1, induce EMT and anoikis-resistance.
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has undetectable GRHL2 expression, while
other mouse mammary lines that are
unresponsive do express GRHL2 (figure S7).
These results are consistent with the previous

finding that additional factors from the tumor microenvironment confer TGF-β−responsiveness upon HMLE
cells, suggesting that one or more of these factors could function by down-regulating GRHL2 (7). More
generally, the GRHL2 expression profile in breast cancer samples and cell lines indicate that GRHL2 is a
general barrier to EMT. Accordingly, GRHL2 prevented TGF-β from conferring anoikis-resistance,
mammosphere formation (a tumor initiating cell behavior), and invasive growth in three-dimensional culture,
predicting a tumor-suppressive effect in this context.
These results also suggest that GRHL2 may be a useful biomarker for tumors predicted to respond to TGF-β
receptor inhibitory drugs currently in clinical trials (41): GRHL2-null tumors, being susceptible to the tumorpromoting effects of TGF-β, are predicted to respond specifically to this class of drugs, an approach that could
improve their efficacy substantially.
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Figure S1. GRHL2 is down-regulated in clear
cell Renal Cell Carcinoma (ccRCC). Primary
data were derived from the NCBI-GEO
database GSE15641 from the study by Jones,
et al. (Clin Cancer Res 2005;11:
5730-9)

Figure S2. TGF-b is critical for EMT and anoikis-resistance induced by Twist.
HMLE+Twist-ER cells were induced with 4-OHT, to activate the twist-ER
protein, in the presence or absence of LY364947. Cells were assayed for
epithelial and mesenchymal marker genes (western blot, upper left panel),
morphology (phase contrast, lower left panel), anoikis (DNA fragmentation
ELISA, upper right panel) or E-cadherin and vimentin staining
(immunofluorescence, lower right panel).
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Figure S3. GRHL2 suppresses EMT-related invasive growth. (left
panels): HMLE+Twist-ER cells (no 4-OHT) with GRHL2 shRNA
or scrambled control shRNA were induced with TGF-β and assayed
for invasive growth in three-dimensional matrigel culture. (right
panels): HMLE+Twist-ER cells (induced with 4-OHT) infected with
empty vector or GRHL2 expression vector were assayed similarly.
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Figure S4. TGF-b is critical for EMT induced by
shGRHL2 in HMLER cells. The
HMLER+shGRHL2a cell line was incubated with or
without LY364947 and analyzed for morphology
(phase-contrast, top panel), E-cadherin
expression/localization (left panel) and epithelial and
mesenchymal markers (western blot, right panel).

Figure S5. Re-expression of ZEB1 in MSP cells with
constitutive GRHL2 expression restores EMT. MSP+GRHL2
that were transduced with a doxycycline-inducible ZEB1
expression vector were analyzed for epithelial and mesenchymal
markers (western blot, upper panel) or E-cadherin
expression/localization (immunofluorescence, lower panel).

Figure S7. Comparison of GRHL2 expression in
the TGF-β−responsive mouse mammary
epithelial cell line NMuMg vs. two nonresponsive lines, SCP2 and Eph4.

Figure S6. ZEB1 shRNA reverses EMT in HMLER/sh-GRHL2 cells.
HMLER expressing shGRHL2a that were transduced with two distinct
ZEB1 shRNAs or a scrambled shRNA control were analyzed for
epithelial and mesenchymal markers (western blot, top panel), Ecadherin (immunofluorescence; lower panel; note that RFP and GFP
signal from the shRNA vectors was quenched by the use of methanol
fixation), or cell morphology (right panel).

53

Chapter 3
A RECIPROCAL FEEDBACK LOOP BETWEEN GRAINYHEAD-LIKE-2 AND
ZEB1
CONTROLS EMT AND TUMOR SUPPRESSION
This manuscript is being revised for re-submission to Cancer Research
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Abstract
The oncogenic Epithelial-Mesenchymal Transition (EMT) enhances malignant progression by promoting
invasion and survival of tumor cells. EMT is induced by microenvironmental factors including TGF- and
Wnt agonists, and transcription factors including the E-box binding factors Twist, Snail and ZEB.
Previously, we reported that a member of the mammalian Grainyhead family of wound healingregulatory transcription factors, Grainyhead-like-2 (GRHL2), is a potent, generalized suppressor of EMT
that functions by repressing ZEB1 expression and inhibiting TGF- signaling. Here we elucidate the
functional relationship between GRHL2 and ZEB1 in EMT/MET and tumor biology. At least three
homeodomain proteins, Six1, LBX1, and HoxA5, transactivated the ZEB1 promoter; for Six1, this was
through direct protein-promoter interaction. GRHL2 inhibited this transactivation and altered the Six1DNA complex. Correspondingly, GRHL2 expression prevented tumor initiation in xenograft assays, a
measure of cancer stem cell frequency. GRHL2 sensitized breast cancer cells to taxol, and prevented the
taxol-driven emergence of cancer stem cells. GRHL2 was down-regulated in recurrent, oncogeneindependent, mouse tumors, supporting a role for GRHL2 down-regulation in tumor evolution to an
EMT/stem cell-enhanced phenotype. Conversely, the combination of TGF- and Wnt activation
repressed GRHL2 expression through direct interaction of ZEB1 with the GRHL2 promoter, inducing
EMT. These observations indicate that a reciprocal feedback loop between GRHL2 and ZEB1 controls
epithelial vs. mesenchymal phenotypes and EMT-driven tumor progression.
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Introduction

The oncogenic epithelial-mesenchymal transition (EMT) contributes to tumor progression by enhancing
tumor cell invasiveness and anoikis-resistance, which may enhance the early steps of metastasis, as has been
demonstrated in certain contexts. Chemoresistance and radioresistance also accompany EMT, confounding
patient responses to treatment (1-4), especially pronounced in, for example, the claudin-low subclass of breast
cancer, where a frank EMT-like pattern of genes is expressed.
EMT also provides a permissive cellular environment for expression of the cancer stem cell/tumor initiating
cell phenotype, thus increasing the probability of tumor initiation. Only a fraction of the cells that have
undergone EMT adopt cancer stem cell characteristics, and recently emerging data suggest that cancer stem
cells with an epithelial phenotype may exist as well (5). Nevertheless, compelling evidence for the EMT/stem
cell connection exists in cell culture, mouse models and analysis of patient samples (6-9).

The cancer stem

cell/tumor initiating cell phenotype, which was initially assumed to be cell-intrinsic, is now known to be
dynamic, as is the EMT phenotype. Tumor stem cells inter-convert with non-stem cells in response to microenvironmental signals (6, 10, 11). Analogously, basal and luminal mammary epithelial cells are interconvertible (11, 12). The hope arising from this body of work is that manipulating factors in the tumor microenvironment, whether arising from autocrine or paracrine signaling, can reprogram cancer stem cells to become
non-stem cells, improving treatment outcome. In particular, cancer stem cells, which emerge during the course
of chemotherapy, are thought to be the primary precursor cells for disease recurrence, indicating the importance
of understanding how they are generated and/or suppressed.
The barrier to this progress resides in the apparent diversity of EMT/stem cell regulatory genes and
signaling pathways, For example, there is a complex network of receptor signaling, transcription factors, cell
adhesion factors and cell cohesion factors determining the epithelial vs. mesenchymal phenotype. This
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complexity seems therapeutically confounding. But, a cancer stem cell phenotype represents a commitment to
autocrine signaling pathways that render the cell semi-autonomous (6). An understanding of how this autonomy
is achieved would provide an Achilles heel for suppressing the cancer stem cell in breast cancer, significantly
promoting long-term response to chemotherapy.
The transcription factors ZEB1 and ZEB2 (SIP1) are pivotal activators of EMT. ZEB1 and, subsequently,
ZEB2 were originally identified as the first repressors of the mammalian E-cadherin promoter (13). They are
now known to regulate cytoskeletal, cell polarity, cell adhesion and apoptosis-regulatory genes that collectively
suffice for EMT induction. ZEB1 is induced by transcription factors that include NF-kB (14), Twist/Snail,
acting in concert (15)), TCF4 (16) and LBX1 (17). Conversely, ZEB1 expression is translationally attenuated
by mir-200b/c, whose expression is, in turn, repressed by TGF-β signaling, explaining (in part) the engagement
of stable autocrine TGF-β signaling in the maintenance of EMT.
Grainyhead-like-2 is a transcription factor that regulates wound healing, epidermal junction assembly, and
neural tube closure, processes related to or regulated by EMT (18-21). Previously, we reported that GRHL2 is
a generalized suppressor of oncogenic EMT, through at least two mechanisms, direct repression of ZEB1
expression and inhibition of the TGF-β pathway. Here, we show that GRHL2 inhibited transactivation of the
ZEB1 promoter mediated by the homeodomain proteins Six1, LBX1 and HoxA5. GRHL2 acted as a tumor
suppressor gene in an assay for the frequency of tumor initiation, a measure of cancer stem cell abundance,
indicating that it suppressed the cancer stem cell phenotype. Consistent with this, GRHL2 sensitized tumor cells
to a chemotherapy agent in culture and prevented the emergence of cancer stem cells during treatment with this
agent. The combination of Wnt and TGF-β pathway activation up-regulated ZEB1 expression.

ZEB1

reciprocally repressed GRHL2 expression through a direct interaction with the GRHL2 promoter. This revealed
a novel GRHL2-ZEB1 reciprocal negative feedback loop that drives EMT vs. MET in response to extracellular
signals.

Materials and Methods
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Cell lines: HMLE and HMLE+twist-ER were kindly provided by R. Weinberg (Whitehead Institute); MDAMB-231LN were from E. Pugacheva (West Virginia University). Cells were cultured and stable cell lines were
generated via retroviral transduction as described previously (22) GRHL2 was expressed using either MSCVIRES-puro or MSCV-IRES-GFP (pMIG, Addgene) and mixed populations were used (except in the case of
GRHL2/MSCV-IRES-puro, where a strong selection for GRHL2-negative cells necessitated the use of clonal
populations to achieve 100% positivity). The

-catenin S33Y mutant (provided by S.P.S. Monga, University of

Pittsuburgh) was subcloned into the pMXS-IRES-PURO retroviral vector (contributed by Russ Carstens ,
University of Pennsylvania in-frame with a C-terminal FLAG tag). The human Six1 sequence was also
subcloned into the pMXS-IRES-PURO vector. ZEB1 shRNA (V3LHS_356186, Open Biosystems) and ZEB1
cDNA were expressed via the pTRIPZ and pLUT lentivrial vectors, respectively, as described previously (22).
Human H-rasV12 in MSCV-IRES-Blast (Addgene) was used to express activated Ras in CD44low (flow-sorted)
HMLE cells for tumor assays described below. HMLE+Ras cells were subjected to stable GRHL2 knockdown
(Open Biosystems RHS4430-99291384) using the pGIPZ, followed by selection for puromycin resistance and
sorting for GFP.
Xenograft Assays: MDA-MB-231LN stably expressing either empty-MSCV-IRES-Puro or GRHL2-IRES-Puro
were trypsinized and re-suspended in growth media and 1x105 cells in 0.1 ml were injected into the 4th inguinal
mammary fat pad of female BALB/c nude mice (Charles River) at approximately 4 weeks of age. HMLE+Ras
cells with GRHL2 or control shRNA (see above) were trypsinized and suspended in growth medium; 1x106
cells were injected in 0.1ml into the 4th inguinal mammary fat pad of female NOD/SCID (Charles River).
Assays were carried out for 8 weeks. Tumor volume was determined using the formula π(L1×L22)/6, where L1
is the long axis and L2 is the short axis. Tumor burden was monitored according to the WVU ACUC Tumor
Burden Policy. Animal studies were approved by the West Virginia University Animal Care and Use
Committee.
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Western blotting: Electrophoresis, transfer, immunoblotting and antibodies used were described in (22). Other
antibodies used here were: rabbit anti-vimentin (Cell Signaling), mouse anti-FLAG (M2; Sigma) and mouse
anti-GAPDH (Thermo Scientific).
Chemosensitivity assays: MDA-MB-231 cells with stable GRHL2-MSCV-IRES-puro or empty MSCV-IRESpuro were plated in 96-well dishes at 5,000 cells per well and assayed in triplicate for cell viability after three
days of incubation, with the indicated concentration of paclitaxel, using Presto-Blue (Invitrogen) according to
the manufacturer’s protocol. For the chemo-induced stem cell analysis, the protocol was modeled after (7).
HMLE cells expressing empty-MSCV-IRES-GFP or GRHL2–MSCV-IRES-GFP were treated with paclitaxel
(10nM) for 4 days, followed by 7 days recovery and flow analysis for CD44 using a CD44-PE antibody (BD
Biosciences). HMLE induced to undergo EMT by ectopic twist were used as a positive control for the CD44high
phenotype.
qRT-PCR analysis of primary vs. recurrent mouse tumors: RNAs from primary and recurrent tetO-neuNT (23)
or tetO-Wnt1 (24) were provided by L. Chodosh (University of Pennsylvania) or E. Gunther (Penn State
University, Hershey) and analyzed for GRHL2 expression using a β2-microglobulin internal control as
described previously (22), using the primers: mGRHL2-f: caaggacgaccagcgcagca; mGRHL2-r:
ggccctccccctgcttctga; mB2M-f: tggtctttctggtgcttgtc; mB2M-r: gggtggaactgtgttacgtag
BIO, TGF-β and BMP2 treatments: HMLE cells were treated with 5

M 6-bromo-3-[(3E)-1,3-dihydro-3-

(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-(3Z)-2H-indol-2-one (BIO;(25)) and/or TGF-β1 (5ng/ml) for
4 days. BIO was removed and the TGF-β was continued for another 6 day; samples were then analyzed by
western blotting. HMLE+twist-ER were treated with either 50 nM 4-hydroxy-tamoxifen (4OHT), 0.5 µg/ml
BMP-2 (R and D Biosystems) or both for 7-10 days and then analyzed by western blotting.
Reporter Assays: Co-transfections, luciferase and β-galactosidase assays as well as the GRHL2 expression
vector and ZEB1-WT- promoter reporter were described previously (22). The transcription factors used in the
co-transfection/reporter assays were obtained and cloned as follows: hLBX1 was obtained from D. Haber
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(Dana-Farber Cancer Center) in pBABE and cloned into pCDNA3.1. hHOXA5 was purchased from Addgene
and subcloned from pET28B into pCDNA-3.1. mTwist (pBABE-mTWIST-ER) was purchased from Addgene
and the twist cDNA was subcloned into pCDNA-3.1 (GC rich Phusion buffer). HA-Snail-pCDNA-3.1 was
purchased from Addgene. The GRHL2 genomic sequence from

-625 to +335 (relative to the transcription

start site of the standard GRHL2 transcript) was subcloned into pGL4.14 using the following primers: Graprom-f3: CTCACCTGTTTGAAAATCTG and Gra-prom-r12: TGTTTGATCCAATGAACTTGC, using the
Bacterial Artificial Chromosome clone 2058A8 (Invitrogen) as a template; these coordinates were based on the
GRHL2 transcript NM_024915. The band resulting from this PCR was re-amplified with similar primers
containing NheI (forward) and BglII (reverse) restriction sites, and subcloned into pGL4.14 (Promega).
The ZEB1 promoters containing a mutant downstream homeobox site or deleted upstream homeobox
site or both were generated as follows.

The downstream site was mutated by using the mutagenic primers

Mut-f3: cgtgcctccctctccccaccagtccgtaggaaaacttttccc Mut-r3: gggaaaagttttcctacggactggtggggagagggaggcacg in
the Quickchange-IIXL kit (Agilent) with the ZEB1 promoter/pGL3basic clone (provided by Antonio Garcia de
Herreros, University of Barcelona) as a template. The deletion of the upstream site was generated by
amplifying the same template in two separate PCR reactions, using Ant-f:
TAATTTACGCGTCCTTAAGGTCCTGCACGGCG, Antr: TTTAAAAAGCTTCCGCCATGATCCTCTCGC (reaction 1) and Ant-f2:
tatataGCGGCCGCAAGGGAAGGGAAGGGAGTCC, Ant-r2:
TTTAAAGCGGCCGCTTCAATGAGATTGAACTTCA. Following restriction digestion and isolation from an
agarose gel, fragments were three-way ligated into pGL3basic.
Chromatin Immunoprecipitation (CHIP) assays: The protocol for crosslinking, immunoprecipitation,
de-crosslinking and qPCR analysis was as described (22). For Six1 protein interaction with the ZEB1 promoter,
5 dishes of HMLE+ empty vector (pMXS-IRES-puro) or FLAG-Six1 were immunoprecipitated with mouse
anti-FLAG-M2-agarose or mouse IgG (Santa Cruz BioTechnology)-agarose in conjunction with DNA/proteinblocked protein A/G agarose (Pierce/Thermo). Primers to amplify the ZEB1 promoter were: f:
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gccgccgagcctccaacttt; r: tgctagggaccgggcggttt. For interaction of ZEB1 protein with the GRHl2 promoter, 5
dishes HMLE expressing ZEB1 (in pLUT vector) were processed. To pull down ZEB1 1 ug of the following
antibodies (3 ug total) were used: ZEB1, rb, Sigma HPA004820; ZEB1, rb, Cell Signalling 3396S; ZEB1, rb,
Santa Cruz Biotechnology SC-25388. Control antibody was rabbit IgG (3 ug) Santa Cruz Biotechnology.
Primers to analyzed the ZEB1 chIP were: Positive control: Ecad-ZEB1-f: ggccggcaggtgaaccctca; Ecad-ZEB1-r:
gggctggagtctgaactga; GRHL2 promoter set 3: f: cgccgctccactcgggtaaa ; r: tgcgcgatgattggctgggg; GRHL2
promoter set4: f: tcagctctcacaggctgccg; r: gaggcgcgctcaggtaaggc. Negative control primer set for all CHIP
assays was from an intergenic region upstream of the GAPDH locus: GAPDH-f: atgggtgccactggggatct;
GAPDH-r: tgccaaagcctaggggaaga.
Electrophoretic mobility shift assay: Purified recombinant Six1 protein was generated as described previously
(26). Purified recombinant GRHL2 protein was obtained by expressing the GRHL2 coding sequence in E. coli
BL21 using the pGEX-6P3 vector and purifying the fusion protein as described previously (13). After binding
to the Glutathione Sepharose resin (GE Healthcare) the protein was cleaved free of GST sequence using PreScission Protease, which was then dialyzed against EMSA buffer (see below) using Slide-A-Lyzer Minidialysis Unit (Thermo Scientific). 2x EMSA buffer was: 30mM HEPES pH 7.6, 20% Glycerol, 1mM EDTA,
200mM KCL, 0.5% NP40, 5mg/ml BSA (added fresh), 10mM DTT (added fresh). For 20ul binding reactions:
10ul 2x EMSA Buffer+1 uL poly dIdC (0.5 ug/uL)+2

L annealed 100 nM oligonucleotide, and recombinant

protein (as indicated). Oligonucleotides for EMSA were synthesized with Cy5 groups on both 5’ ends (Operon)
and annealed at 10 mM Tris/1mM EDTA/100mM NaCl. Binding reactions were incubated at 4 degrees for
twenty minutes, fifteen minutes at room temperature and analyzed on 6% polyacrylamide/TBE gels in 0.25x
TBE buffer (pre-run for 1h) at 170V. The fluorescent signals were imaged using the LiCor Odyssey imaging
system.
Oligo sequences(Forward strands)
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ZEB1-WT-Promoter: (Cy5)GGAAGGTGATGTCGTAAAGCCGGGAGTGTCGTAAACCAGGTGCGGTGGG
ZEB1-MT-Promoter: (Cy5)GGAAGGTGATGTCGTCCCGCCGGGAGTGTCGTCCCCCAGGTGCGGTGGG
GRHL2-Pos-Con: (Cy5)-AACTATAAAACCGGTTTATCTAGTTGG
Six1-Pos-Con: (Cy5)-GGGGGCTCAGGTTTCTGTGGC
Negative Control (From E-cadherin promoter):
TGGCCGGCAGGTGAACCCTCAGCCAATCAGCGCTACGGGGGGCGGTGCTCCGGGGCTCACCTGGC
TGCAG
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Results
GRHL2 inhibits the activation of ZEB1 expression by homeodomain proteins
Previously, we reported that GRHL2 binds and represses the ZEB1 promoter so as to suppress EMT (22). To
characterize this transcriptional regulation further, we analyzed the ZEB1 promoter using a transcription factor
binding prediction program (Genomatix) and identified two tandem homeodomain consensus binding sites,

Figure 1. (a) The region of interest from the ZEB1 promoter is conserved between various species: Ms: Mus
musculus, Hs: Homo sapiens, Bp: Bos primigenius, Dr: Danio rerio. Bold=homeobox consensus sites;
Italics=grainyhead consensus sites. (b). LBX1 and Six1 activate transcription from the ZEB1 promoter in a GRHL2sensitive manner. The ZEB1 promoter-luciferase reporter with wild-type sequence (WT), the 3’ homeobox site
mutated (MUT) or both the mutation of the latter site plus deletion of the 5’ homeobox binding site (DD) were cotransfected into MSP cells together with the indicated transcription factors. (c). HoxA5 activates transcription
from the ZEB1 promoter in a GRHL2-sensitive manner. The wild-type reporter was co-transfected into MSP cells
together with HOXA5 and various amounts of GRHL2 constructs.

overlapping with and just upstream of the putative GRHL2 site (Figure 1a). Alignment of this sequence
between several species revealed that both the putative GRHL2 binding site as well as these homeobox sites
were highly conserved. In this light, we tested the effect of two homeodomain factors that were previously
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shown to be involved in EMT induction in breast cancer cells, LBX1 and Six1, on the activity of the ZEB1
promoter (17, 27). These factors activated transcription of the ZEB1 promoter significantly (Figure 1b,c).
HoxA5, another factor that was predicted to bind these two sites, also demonstrated robust activation as well as
the ability to induce mammosphere
formation in HMLE cells, although
frank EMT was not evident (figure S1,
data not shown). Mutation of the 3’
homeodomain binding site
substantially diminished
transactivation by these factors. The
Figure 1d. GRHL2 and Six1 bind specifically to sequences in the ZEB1
promoter. Wild-type (wt) or mutant (mut) oligonucleotides corresponding
to the conserved sequence of interest from the ZEB1 promoter were used to
analyze and demonstrate the specificity of GRHL2 protein (left) or Six1
(right) protein interactions.

double deletion totally eliminated it,
and, interestingly, GRHL2 cotransfection inhibited the

transactivation by all three factors (Figure 1b,c, S3).
LBX1 was shown previously to interact directly with the ZEB1 promoter and to activate its expression
(17). We tested Six1 for selective,
direct binding to an
oligonucleotide corresponding to
the conserved sequence of the
ZEB1 promoter. Six1 protein
interacted preferentially with the
wild-type but not the doubly
Figure 1e. GRHL2 alters the Six1-DNA complex. GRHL2 positive control oligo
(GRHL2PC), Six1 positive control oligo (Six1PC), oligo from the E-cadherin
promoter which neither protein is predicted to bind (Neg), and WT ZEB1
promoter oligo were used in an EMSA with the indicated combinations of GRHL2
and Six1 proteins.
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mutated (transcriptionally
inactive) sequence, as did GRHL2

protein (figure 1d). The addition of stoichiometric amounts of GRHL2 protein diminished the Six1-DNA
complex dramatically, indicating either a competition for DNA binding or an inhibitory Six1-GRHL2
interaction, which the data do not allow us to distinguish (figure 1e).
We then tested the effect
of Six1 on endogenous
ZEB1 expression. HMLE
cells are a mixed
population containing 510% CD44highCD24low
mesenchymal cells in
Figure 1f (left) and 1g(right) (f) Six1 induces the endogenous ZEB1 gene and EMT in
unfractionated HMLE cells. HMLE cells expressing vector or FLAG-Six1 were analyzed for
the indicated EMT markers (upper panel); or morphologic changes (lower panel). (g). Six1
protein interacts with the ZEB1 promoter in vivo. Chromatin from HMLE expressing
either vector or FLAG-Six1 were used in a CHIP assay and analyzed by QRTPCR using
ZEB1 promoter primers or GAPDH control primers.

equilibrium with
epithelial cells (7).
Mixed-population HMLE

cells or flow-sorted CD44low HMLE cells, with or without shRNA-mediated GRHL2 knockdown, were infected
with Six1 retroviral expression constructs. Interestingly, Six1 by itself up-regulated ZEB1, down-regulated
GRHL2 and induced EMT in the unfractionated HMLE cells (figure 1f). In flow-sorted CD44low cells,
induction of ZEB1 expression required Six1 expression plus the concomitant knockdown of GRHL2 through an
shRNA (previously shown to have identical effects with other shRNAs targeting GRHL2), consistent with the
antagonistic effect of GRHL2 that we observed previously (figure S2, (22)). CHIP analysis of the mixedpopulation cells revealed that Six1 was recruited to the endogenous ZEB1 promoter, indicating a direct Six1
protein-ZEB1 promoter interaction (figure 1g).
Knockdown of the individual homeodomain proteins examined here failed to block ZEB1 induction
during EMT, indicating that multiple redundant factors, likely to include additional, unidentified factors,
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activate ZEB1 (data not shown). Nevertheless, the combined data support a model under which GRHL2 is a
general inhibitor of homeodomain-induced ZEB1 expression.
GRHL2 suppresses primary tumor growth and sensitizes tumor cells to the chemotherapy-induced cytotoxicity

Previously, we reported that GRHL2 suppressed or reversed the oncogenic EMT, in part, through the
repression of the ZEB1 gene (22). EMT increases the frequency of breast cancer stem cells (CSC), and
consistent with this, GRHL2 suppressed mammosphere generation and down-regulated CD44 (22, 28). Here,
we tested the effects of GRHL2 on tumor initiation frequency, a measure of CSC frequency. HMLER cells are
immortalized mammary epithelial cells that express HrasV12 ectopically and have not undergone EMT, but are
induced to do so by stable GRHL2 knockdown using
multiple, independently targeting shRNAs (22, 29). As
reported previously, the input cell number (1x106) of
parental HMLER cells (with control shRNA) that we
injected into immuno-compromised mice produced no
detectable tumors (figure 2A; (28). By contrast, a
representative GRHL2 knockdown derivative cell line
usually (6/8) formed tumors. To extend this to another
cell line, the triple-negative breast cancer lines, MDAMB-231, with or without ectopically expressed GRHL2,

. (A) GRHL2 suppresses tumor initiation.
Immunodeficient mice were injected orthotopically
with pre-optimized cell numbers of MDA-MB231LN cells expressing GRHL2 vs. empty vector
(left) or HMLE+Ras cells expressing GRHL2 shRNA
vs. control shRNA (right). Results shown are based
on measurements at five weeks and eight weeks,
respectively. N=8 per group of HMLER and N=6 per
group of MDA-MB-231LN. P-values are shown
below the graphs.

(22) were injected. GRHL2 suppressed the frequency of tumors dramatically (5/6 vs. 0/6). These data were
consistent with a tumor-promoting effect of EMT (7, 28, 30) that GRHL2 suppressed. In conjunction with the
functional assays and clinical correlations – downregulation of GRHL2 expression in EMT-like tumors -- that
we published previously (22), these results identify GRHL2 as a tumor suppressor gene.
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EMT is associated with chemoresistance (31, 32). We reasoned that the mesenchymal to epithelial
transition induced by GRHL2 would be associated with enhanced sensitivity to the microtubule-targeting
chemotherapy drug, paclitaxel.
Ectopic GRHL2 expression
induced dose-dependent cell
death in the otherwise refractory
MDA-MB231LN tumor cell line
(Figure 2b). HMLE cells contain
a sub-fraction of
GRHL2 sensitizes tumor cells to paclitaxel: dose response comparing cell survival
of MDA-MB-231LN cells with or without stable GRHL2 expression. (c) GRHL2
suppresses the emergence of stem cells after paclitaxel treatment: CD44 flow
cytometric analysis, of HMLE cells with or without GRHL2 transgenes. (d) Loss of
GRHL2 from the population of taxol-treated HMLE cells; note the up-regulation of
CD44 in these cells as well (lanes 1 and 3), which was suppressed by a GRHL2
transgene (lanes 2 and 4).

CD44highCD24low
mesenchymal/stem-like cells,
which are enriched by paclitaxel

selection (7, 32). We confirmed
that, following paclitaxel treatment
and recovery, essentially 100% of
HMLE (control) cells exhibited a
CD44high phenotype, analogous to
Figure 2e. GRHL2 is down-regulated during the transition from primary to
recurrent phenotype in tetO-Wnt1 and tetO-neuNT mouse models: qRT-PCR on
RNAs from independent tumors, normalized against 2-microglobulin.

that induced by ectopic twist
expression; these cells also

expressed lower levels of GRHL2 than the original population. By contrast, ectopic GRHL2 expression
prevented the chemotherapy-induced emergence of CD44high stem like cells, consistent with its suppression of
EMT (figures 2c,d and (22)).
In doxycyline-inducible mouse mammary tumor models models, the expression of neuNT, Wnt1 or c-myc
promotes primary tumors that regress upon the removal of doxycyline. The tumors recur frequently, and the
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recurrent tumor cells have undergone EMT, providing a model for evolution from oncogene/proliferation ratedriven tumors to oncogene-independent, EMT-driven recurrences (23, 24, 33). We analyzed RNA from the
tetO-neuNT and tetO-Wnt1 mouse models for GRHL2 expression by qRT-PCR. In both cases, GRHL2
expression was greatly reduced in the recurrent tumor relative to primary (figure 2e). These findings indicate
that GRHL2 is down-regulated during tumor evolution to an EMT phenotype, further supporting the tumor
suppressor function of GRHL2.
Based on the extensive data supporting an oncogenic role for EMT, the suppression of EMT by GRHL2,
the effects of GRHL2 on tumorigenicity and chemo-sensitivity, and the down-regulation of GRHL2 during
EMT in cell culture, patient and mouse models, we set out to identify pathways that down-regulate GRHL2
expression.
GRHL2 is down-regulated by Wnt and TGF-β
TGF-β is able to induce EMT in only restricted cell contexts (34). In HMLE cells, TGF-β induced EMT only
in conjunction with Wnt pathway agonists or in cells where GRHL2 had been knocked down, providing insight
into this restriction (7, 22).

Figure 3a(left) and 3b(right) HMLE cells treated with the Wnt pathway
agonist BIO (a) or stably expressing β-catenin S33Y (b) were assayed for
GRHL2 down-regulation in response to TGF- treatment by Western
blotting.

Activation of the Wnt signaling pathway by transient
treatment with the GSK-3 inhibitor, 6-bromo-3-[(3E)-1,3-

Figure 3c. HMLE cells that stably
expressed Twist-ER protein were treated
with or without 4-OHT (to activate TwistER) in the presence or absence of the TGF pathway antagonist BMP2, and cell
lysates were assayed for GRHL2 and other
indicated protein expression.

dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-(3Z)-2H-indol-2-one (BIO;(25)) or, by stable
expression of the degradation-resistant

-catenin S33Y mutant (35), down-regulated GRHL2 expression only
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modestly in this short-term assay, as did extended treatment with TGF-β. Co-activation of both pathways,
however, caused a dramatic down-regulation of GRHL2 expression (figure 3a,b), accompanied by upregulation of the GRHL2-repressed target gene, ZEB1. BMP2, a functional antagonist of TGF-β signaling and
Twist-induced EMT (7, 36), alleviated both GRHL2 down-regulation and ZEB1 induction in response to the
activation of Twist-ER protein by 4-hydroxytamoxifen (figure 3c).

These observations signified that Wnt and TGF-βpathways collaborated to down-regulate GRHL2 as an
intermediate step in EMT, and prompted us to investigate the potential role of ZEB1 in this down-regulation.
ZEB1 represses the GRHL2 promoter directly
To test the role
of ZEB1 in the downregulation of GRHL2,
HMLE cells with an
Figure 1. (a): si/shRNA mediated knockdown of ZEB1 partially alleviated GRHL2 downregulation caused by 4-OHT-activated Twist-ER protein (a) or BIO plus TGF- treatment (b).
(c): HMLE stably expressing a doxycycline-inducible ZEB1 expression construct were
induced with doxycycline and lysates were analyzed for ZEB1, GRHL2, E-cadherin and Akt by
Western blotting.

estrogen-inducible
Twist fusion protein

(HMLE+Twist-ER) were induced to
undergo EMT by the addition of 4hydroxytamoxifen. As we reported
previously, this up-regulated ZEB1
and down-regulated GRHL2 (22).
The GRHL2 promoter in a luciferase reporter vector was co-transfected
with Snail, Twist or ZEB1 expression vectors in HMLE cells or the promoter
was transfected by itself into MSP cells; normalized luciferase activity
values are shown. (e) HMLE-MSP transfected with control or ZEB1 siRNA,
were transfected with the GRHL2 promoter-luciferase construct;
normalized luciferase activity values are shown.
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Suppression of ZEB1 with siRNA,
however, largely prevented the
GRHL2 down-regulation (figure 4a).

To test this in a different context using a different knockdown reagent, HMLE cells with stable GRHL2 shRNA
expression or empty vector control cells were induced with the combination of BIO and TGF-β. Analogously,
depletion of ZEB1 by GRHL2 shRNA (targeting a different sequence) alleviated the down-regulation of
GRHL2 (figure 4b). Conversely, we expressed ZEB1 ectopically in HMLE cells using a doxycycline-inducible
lentiviral vector. Induction of ZEB1 down-regulated GRHL2 expression as well as the previously characterized
ZEB1 target, E-cadherin ((13) and figure 4c).
We then explored the possibility that ZEB1 protein might repress the GRHL2 gene through direct interaction
with promoter sequences. As an initial test, we subcloned a genomic fragment containing the sequences from 625 to +335 (relative to the transcription start site of the standard GRHL2 transcript) into a luciferase reporter
vector and assayed this for transcriptional activity. The transcriptional activity of this promoter clone was
substantially greater in HMLE cells than in the mesenchymal subpopulation (MSP) cells derived from HMLE,
consistent with the downregulation of endogenous GRHL2
in the latter, validating this
promoter clone ((22) and figure
4d). Co-transfected ZEB1
repressed the promoter, nearly to
background level. By contrast,
two other E-box binding EMTrelated transcription factors, Snail
CHIP–seq data (Encode project;(50)) for ZEB1 reveal a potential binding site
near the transcription start site. (b) Confirmation of CHIP-seq. Chromatin from
HMLE expressing tet-ON ZEB1 were subjected to chIP using ZEB1 antibody and
analyzed by qRTPCR using the indicated primers.

and Twist, only modestly
repressed the promoter.

Conversely, the promoter activity assayed in MSP cells was stimulated by transfection of ZEB1 siRNA (figure
4e).
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Inspection of published ZEB1 CHIP-seq data indicated binding sites positioned near the transcription start site
of GRHL2 (Figure 5a). By CHIP analysis using anti-ZEB1 antibody, we detected an interaction of ZEB1
protein with GRHL2 sequences near the transcription start site, with efficiency comparable to that of the Ecadherin promoter and significantly stronger than a negative control sequence (the intergenic region upstream of
the GAPDH gene; figure 5b). When combined, these data indicated that ZEB1 protein represses the GRHL2
promoter directly, establishing that a mutual antagonism between expression of ZEB1 and GRHL2 directs
tumor cells toward epithelial or mesenchymal phenotypes.
Discussion
Our observations inform a model of reciprocal antagonism between ZEB1 and GRHL2 as a pivotal
mechanism underlying EMT (figure 6). Under this model, GRHL2 and ZEB1 – each regulated by microenvironmental factors – repress each other’s transcription. GRHL2 represses ZEB1 by inhibiting at least three
activators of the ZEB1 promoter: LBX1, Six1 and HoxA5.
We focused on these three transcription factors in light of the functional importance of homeodomain
consensus sites for activity of the ZEB1 promoter (figure 1). Although numerous homeodomain proteins may
have partially redundant functions, confounding efforts to show an effect of knockdown/knockout of an
individual factor, their overall significance in diverse cancer types is established (reviewed in (37)). In
particular, previous reports have implicated LBX1 and Six1 in breast cancer-related EMT (17, 27, 38). While
Six1 was shown previously to induce ZEB1 expression, this was proposed to be post-transcriptional in
colorectal cancer cell lines (39), in contrast with our evidence indicating a direct interaction of Six1 with the
ZEB1 promoter; the basis for this discrepancy is unclear.
Importantly, GRHL2 protein, the first direct transcriptional repressor of the ZEB1 gene to be reported
(22), interfered with the transcriptional activation of the ZEB1 promoter by all three of these factors. The
precise molecular mechanism underlying this effect remains to be elucidated. While Six1 and GRHL2 proteins
interacted with an overlapping sequence in the ZEB1 promoter (figure 1), a simple competition for DNA
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binding is unlikely because the oligonucleotide probe was in excess. While GRHL2 protein effectively
abolished the Six1 protein-DNA complex on the ZEB1 promoter oligonucleotide that contained two tandem
Six1 binding sites, there was no effect on Six1 protein binding to a positive control sequence containing only
one binding site (data not shown), suggesting that GRHL2 prevents the dimerization of two Six1 protein
molecules on DNA. We were unable to detect an interaction of GRHL2 with Six1 protein in co-transfection
assays (data not shown), suggesting that they interact only on DNA.
The antagonistic effects of GRHL2 vs. ZEB1, mediated, in part, by homeodomain activators of ZEB1,
may relate conceptually to previously reported developmental roles of these genes. GRHL2 is required for
neural tube closure, the stage of development directly preceding delamination. Subsequently, anterior HOX
genes (HoxA1, HoxB1) induce EMT during delamination of the neural crest, through activation of Snail and
Msx1/2 transcription (40). Speculatively, the homeodomain factors may also activate EMT factors such as
ZEB1, thereby repressing GRHL2 expression, which would indicate, analogously, functional opposition of
these factors during development that mirrors their respective oncogenic EMT functions.
We have now shown the other half of the reciprocal feedback loop (figure 6) as well: ZEB1 is also a
direct repressor of GRHL2 (figures 4,5). When combined, this represents switch that dictates cellular
phenotype between epithelial and mesenchymal states, formally analogous to the relationship between ZEB1
and mir200 (41). Thus, the effect of inducing ZEB1 expression by micro-environmental factors is to repress
GRHL2 expression, promoting stable expression of ZEB1. In this connection, we found that neither TGF-β nor
canonical Wnt pathway stimulation was sufficient to induce ZEB1/down-regulate GRHL2; however, the two in
conjunction tipped the balance in favor of ZEB1. This finding is precisely consistent with those showing that
multiple micro-environmental signals are needed to regulate EMT or MET (6, 42) and may prove to be the
underlying mechanism. Other combinations of factors induce ZEB1 and EMT, at least in specific cell contexts,
including TGF-β+ FGF2, TGF-β+ TNF-alpha, TGF-β+EGF(R), TGF-β+mechanotransduction from
extracellular matrix, or factors in the “senescent cell secretory phenotype” (SASP) (14, 43-46). It is also
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notable that Six1 expression activates autocrine TGF-β and Wnt signaling loops, suggesting that it activates
ZEB1 both directly and indirectly (27).
Our results indicate that these combinations of factors may down-regulate GRHL2 as an intermediate
step leading to EMT. Moreover, the suppression of EMT by stable GRHL2 expression suppresses EMT, the
cancer stem cell phenotype and sensitizes tumor cells to the effects of chemotherapeutic drugs. Thus each of
these stimuli could serve as potential targets for therapies aimed at inhibiting the tumor-initiating cell/chemoresistance phenotype that is accompanies GRHL2 down-regulation during chemotherapy-driven tumor
evolution to a recurrent state. Therapeutic stabilization of GRHL2 expression represents a potential treatment
strategy, given its tumor suppressive role described here and its sensitivity to regulation by microenvironmental factors through established receptors. This function of GRHL2 in suppressing tumors agrees
with other recent reports identifying the related gene, GRHL3, as a tumor suppressor in squamous cell
carcinoma that up-regulates the tumor suppressor, PTEN (47, 48). During development, these factors regulate
some unique and some common genes (49), identifying which targets are unique and common in tumor biology
will undoubtedly be the focus of future investigation.
Cellular commitment to undergo an oncogenic EMT is formally analogous to cell cycle control in that
both involve a transition from dependence on extracellular signals to an autonomous, stable state. For example,
the cell cycle becomes autonomous past the mitogen-driven restriction point, activation of cyclinD-CDK4/6
complexes, and maintains that state by a number of mechanisms, including stable activation of cyclin E
expression by free E2F. Similarly, oncogenic EMT is initiated by micro-environmental factors, for example,
TGF-β and Wnt agonists. We propose that the transition to an autonomous state is defined, in part, by downregulation of GRHL2, stabilizing autocrine signaling through ZEB1, TGF-β, Wnt, and other factors. Thus,
GRHL2 down-regulation is an “oncogenic EMT restriction point.”
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SUPPLEMENTAL DATA

Figure S1. Ectopic HOXA5 expression induces mammospheres. HMLE expressing either empty-pBABE puro or
HOXA5-pBABE puro were cultured in methylcellulose with complete medium to test for their ability to form
mammospheres.
Figure S2. SIX1 induces ZEB1 expression only in the context of GRHL2 knockdown, in a CD44low parental cell
line. CD44low HMLE cells expressing empty vector or SIX1, with or without GRHL2 shRNA, were western blotted for
various epithelial and mesenchymal markers.

Figure S3. HOXA5 differentially activates the wild type, single and
double homeobox mutant ZEB1 promoters. MSP derivatives of HMLE
cells were co-transfected with the various ZEB1-promoter luciferase
constructs, with or without HOXA5; the trans-activating factor TFCP2
was included as a negative control.
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Chapter 4
Overall Discussion
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The present work has established that GRHL2 is a potent inhibitor of EMT and can induce MET. This
effect is due, in part, to a direct repression of the ZEB1 promoter by GRHL2. GRHL2 also suppressed TGFβ/Smad dependent transactivation. In-vivo, GRHL2 was down-regulated in human claudin-low breast cancer,
renal cell carcinoma, recurrent tumors in mice and it suppressed tumorigenicity in xenograft assays. In
experimental systems, GRHL2 enhanced anoikis, suppressed anchorage-independent, mammosphere-generating
growth, invasion and sensitivity to chemo-therapeutics. Micro-environmental factors Wnt and TGF-β
collaborated to down-regulate GRHL2 and this was, surprisingly, dependent on direct repression of the GRHL2
promoter by ZEB1. Therefore this thesis has established that GRHL2 is a tumor suppressor gene that engages
in a reciprocal negative repression loop with ZEB1, which regulates EMT and tumorigenicity.
Several other GRHL2 targets that were identified in our microarray analysis represent interesting
opportunities. First, GRHL2 appeared to induce a vestigial-like (VGLL) switch, where VGLL1 was upregulated and VGLL4 was down regulated. Vestigial like genes are co-factors for the DNA binding
transcription factor, TEAD [1]. The role of VGLL’s in vertebrate biology is widely unknown however TEAD
is the transcription factor that YAP and TAZ bind in order to activate transcription. So, by regulating TEAD
binding factors, GRHL2 has the potential to modulate YAP and TAZ function, which as describe in the
introduction, are important regulators of anoikis and EMT. We showed that GRHL2 expression interfered with
the activity of a Smad responsive reporter construct, but the exact mechanism for this was not elucidated. In the
micro array analysis CITED2 was down regulated by GRHL2 and could be the key to this phenomenon.
CITED2 interacts with Smads and serves as a transcriptional co-activator [2], so GRHL2 may regulate the TGFβ/Smad by repressing CITED2. The vitamin D receptor (VDR) was up-regulated by GRHL2 (we confirmed
this by RT-PCR) and VDR can interact with and alter β-catenin transactivation [3-5]. This is one potential
model by which GRHL2 can not only regulate wnt signaling, but could stabilize its own expression based on
what we’ve shown regarding the effect of active wnt on GRHL2 levels. TP63 was shown to be upregulated by
GRHL2 and this was confirmed by RT-PCR (S.F., E.A. unpublished data). Consistent with published data in
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prostate cancer cells and MCF10a [6,7], p63 knockdown induced frank EMT in HMLE (S.F., P.R., E.A.
unpublished data), so it is very likely that the regulation of p63 is a key downstream effector of the GRHL2ZEB1 axis with the precise relationship to be determined by future studies. These are a few representative
examples of intriguing GRHL2 target genes that remain to be tested for their significance in the tumor
suppressive role of GRHL2.
We chose to test the effect of GRHL2 on EMT based on its role in wound healing and regulation of
epithelial adhesion genes. However, we did not examine the other two mammalian grainy-head genes, GRHL1
and GRHL3. Based on the high level of homology of the three mammalian grainyhead genes and the fact that
they share some target genes during development and wound healing (see Introduction), we cannot rule out the
possibility of their functional significance in regulating certain aspects of EMT. In fact, some recently
published data would indicate that this is quite likely. First, GRHL3 (as was GRHL2) was shown to be down
regulated by EMT in prostate cells; this was not a focus of the paper and the significance of GRHL3 down
regulation was not tested [8]. As was noted in the introduction here, GRHL2 and 3 have common and distinct
gene targets, so based on the down-regulation of GRHL3 during EMT its functional significance should not be
ignored. Also, whether GRHL2 regulates epithelial and mesencymal genes as a homo or heterodimer with
GRHL1 or GRHL3 and which genes are unique and common targets remain to be tested. Indeed, GRHL2
expression was sufficient to induce MET, however we did not test whether endogenous GRHL1 or 3 were
involved in this phenomenon.
In anoikis resistant mesenchymal stem cells, mir-125b was shown to be critical for their anchorage
independent survival [9]. Interestingly, mir-125b is predicted to target GRHL1 by the micro-RNA prediction
program “Target Scan”. These data would inform the hypothesis that mir-125b establishes mesenchymal cell
anoikis resistance in part, through GRHL1 down regulation. While a role for GRHL1 in anoikis has not been
shown, its known target gene, DSG1, raises some intriguing possibilities, which warrant experimentation.
DSG1 or desmoglein1 is a component of epithelial desmosomes which are unique cell-cell adhesion complexes.
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It was shown to be co-regulated with E-cadherin and lost in melanoma [10], and while anoikis was not
measured, melanoma cell lines are well known to be anoikis resistant [11-13]. Furthermore, other desmosome
components, DSG2 and PERP have been shown to activate apoptosis [10,14-17]. So GRHL1 may regulate the
anoikis sensitive state of epithelial cells by transcriptionally activating desomsomal genes, which is another
potentially interesting model worth pursuing. Several desmosomal genes were also upregulated by GRHL2 on
our microarray (JUP, PERP, DSG3, DSP, DSC2) indicating that perhaps desomosomal components are general
targets of mammalian grainyhead factors.
Based on this novel role for GRHL2 and the known oncogenic role for EMT, antagonizing pathways
that repress GRHL2 expression and/or function would be the rational basis of MET inducing cancer therapies.
We have identified two pathways, in culture, that collaborate to down regulate GRHL2, Wnt and TGF-β.
Wnt and TGF-β inhibitors could theoretically be tested as a pre-treatment to standard cytotoxic chemotherapies
with the intention of reverting the mesenchymal/ breast cancer stem cell sub-fraction of the tumor to epithelial
and restoring sensitivity to chemotherapy. This could potentially alter the TIC phenotype, which would reduce
recurrences. An analogous strategy is being pursued in glioma where TGF-βR inhibitors have been shown to
revert the CD44HIGH sub population of primary glioma cells, which reduced the tumor initiation frequency
experimentally. Such inhibitors are being tested in glioma clinical trials[18-20]. Other stimuli undoubtedly
regulate GRHL2 expression and await discovery, several external stimuli that regulate ZEB1 and EMT are
listed in the chapter 2 discussions, and they potentially serve as additional targets for the strategy described
here.
Further support for the tumor suppressive role of GRHL2 could be generated by testing the effect of
GRHL2 in additional mouse models. Crossing GRHL2 inducible transgenic lines with the inducible oncogene
models would test the functional significance of the GRHL2 loss that we showed in oncogene independent
recurrences in chapter 3. The prediction would be that stabilizing GRHL2 expression would prevent the
mesenchymal, oncogene independent tumor formation. Also, since the GRHL2 expression prevented tumor
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formation in 231LN xenograft assays, an inducible GRHL2 will be required to test the chemotherapy sensitivity
in vivo. In this experiment 231LN tumor will be allowed to form, followed by induction of the GRHL2
transgene and chemotherapy treatment. Based on the results in culture, the GRHL2 positive tumors will
respond to the treatment while the controls will not.
We also showed that BMP2 stabilized GRHL2 in the context of EMT and two other reports have shown
BMPs to be upstream of grainyhead factors. First in xenopus, GRHL1 expression was shown to be activated by
BMP4 and this was required for epidermal differentiation. [21] And, during the generation of induced
pluripotent stem cells, BMP7 driven MET lead to the upregulation of all 3 mammalian grainyheads [22]. While
it is not clear if this is a direct transcriptional effect of Smad 1 or 5, stimulating BMP signaling could be an
alternative strategy to inducing MET in cancer to elicit the chemo sensitivity effect associated with GRHL2
expression. We have now shown that both GRHL2 stimulates BMP2 expression and BMP2 stabilizes GRHL2.
In contrast to the reciprocal repression between GRHL2 and ZEB1, it appears that GRHL2 and BMP2 engage in
a feed forward loop that stabilizes the epithelial phenotype.
Subsequent to the publication of the role of GRHL2 in regulating EMT/MET presented here in chapter
2, two more reports have now shown the significance of GRHL2 in regulating epithelial morphogenesis and
phenotype in liver and lung cells [23,24]; these data support our findings and suggest that GRHL2 is a master
regulator of epithelial characteristics regardless of the tissue type. The generation of GRHL2 flox/flox mice will
be critical to test its function in vivo in the context of various physiological and pathological processes. Also, in
accordance with the tumor-suppressive role for GRHL2 that we have established, a recent report has shown that
an oncogenic micro-RNA, mir273, targets GRHL2 in breast cancer [25] but the significance of this regulation
was not addressed.
GRHL2 is the first transcriptional repressor of ZEB1 and EMT to be identified. Several inducible
models for EMT exist and include twist-ER, snail-ER(developed by the Weinberg group, MIT) and ZEB182

pLUT(developed by Alexey Ivanov,West Virginia University), these are extremely useful models for studying
the temporal regulation of genes and cellular processes during EMT. Analogous to these, inducible GRHL2
expression in mesenchymal cells can now be used to examine various aspects of the MET process. Also, the
TGF-β field has been limited by the relatively small number of cell lines that respond to TGF-β by undergoing
EMT. Based on our findings, GRHL2 shRNAs provide a rational strategy for inducing TGF-β responsiveness
that widens the context under which it can be investigated.
In conclusion, the research presented in this thesis identifies the transcription factor, GRHL2, as a novel
EMT regulator and tumor suppressor. Identifying pathways which regulate its expression will provide new
targets for cancer therapy based on the suppression of EMT.
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